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Major Depressive Disorder (MDD) is a leading cause of disability worldwide.  Evidence from 
clinical and preclinical models suggests that an important component to MDD is dysfunction in 
the mesolimbic dopamine reward system. This thesis focused on better understanding the brain 
circuits potentially involved in driving this dopamine system dysfunction, as well as mechanisms 
of an antidepressant therapy that directly acts on the dopamine system. We used the chronic mild 
stress (CMS) rodent model of depression, which features a prominent hypodopaminergic 
phenotype, to answer two specific questions: 1) How do brain regions with identified involvement 
in MDD based on clinical literature regulate the dopamine system in normal and CMS-exposed 
rats; and 2) What effect does the atypical antipsychotic agent quetiapine have on normal and CMS-
exposed rats with acute and repeated administration? In each case, we performed single-unit 
recordings of identified ventral tegmental area (VTA) dopamine neurons to assess the dopamine 
system’s functional status. For question 1, we found that activation of the Infralimbic Prefrontal 
Cortex (ILPFC; rodent homologue of human Brodmann Area 25) and Lateral Habenula (LHb) in 
normal rodents each inhibits a distinct subset of dopamine neurons based on their location in the 
VTA, that those inhibited by the ILPFC have greater overlap with those inhibited by CMS than do 
those inhibited by the LHb, and that ILPFC but not LHb inactivation following CMS restores 
dopamine system function to normal levels. For question 2, we found that quetiapine has distinct 
effects on the dopamine system based on duration of administration and history of exposure to 
CMS, with only repeated quetiapine administration restoring dopamine system function in CMS-
exposed rats. Together, these results offer insight to clinically relevant questions regarding 
interactions among brain regions mediating hedonic and affective processes, as well as highlight 
potential dopaminergic mechanisms of novel antidepressant therapies.  
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“The first thing that goes is happiness. You cannot gain pleasure from anything…But soon other 
emotions follow happiness into oblivion: sadness as you had known it, the sadness that seemed 
to have led you here; your sense of humor…Your mind is leached until you seem dim-witted 
even to yourself…Eventually, you are simply absent from yourself.” 
 
–Andrew Solomon, 
The Noonday Demon: An Atlas of Depression 
1 
1.0  GENERAL INTRODUCTION 
1.1 OVERVIEW OF DEPRESSION 
1.1.1 Burden of Depression 
Major depressive disorder (MDD) is a constellation of symptoms including not only sadness and/or 
anhedonia, but also changes in homeostatic function including eating, sleeping, and cognitive 
processes (American Psychiatric Association, 2013). The disorder is very common, affecting an 
estimated 17% of the US population over the course of their lifetime (Kessler, Berglund, et al., 
2005) and 7% of the population at any one given time (Kessler, Chiu, Demler, Merikangas, & 
Walters, 2005). Thus, as one might expect, the human impact of depression is significant. It is 
predicted to be the number one source of disability adjusted life years worldwide by the year 2030 
(World Health Organization, 2008). This is due to a multitude of factors, including a relative lack 
of effective treatments and difficulty appropriately assigning a given treatment to a particular 
patient.  
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1.1.2 Limitations of Current Treatments  
1.1.2.1 Antidepressant Medications 
Unfortunately, depression is extremely difficult to efficiently treat. Only half of patients respond 
to an initial treatment with an antidepressant agent (Trivedi, Rush, et al., 2006), and only one third 
of patients recover from their depression with this medication. Subsequent medication attempts 
result in similarly low rates of remission, regardless of the pharmacological mechanism of the 
second agent selected (Rush et al., 2006; Trivedi, Fava, et al., 2006). Thus a substantial proportion 
of the population experiences treatment resistant depression, defined as a failure to respond to at 
least 4 distinct medications (Nemeroff, 2007).  
Time course is another major limitation of current antidepressant medications. Even when 
medications are effective, often it takes a patient weeks to months to see meaningful clinical 
improvement (Ressler & Nemeroff, 2000). For this reason, there has been significant excitement 
around the recently identified potential antidepressant effects of ketamine (Aan Het Rot, Zarate, 
Charney, & Mathew, 2012). When administered at subanesthetic doses, ketamine can lead to a 
rapid antidepressant effect, which starts typically within 2 hours and may persist as long as 2 weeks 
(Berman et al., 2000). While this prospect is exciting, a major fundamental problem remains in 
that ketamine’s antidepressant effect was discovered serendipitously during its use in other 
investigational means (Krystal et al., 1994). Thus, there exists a major limitation in current 
antidepressant research (and in psychiatry more broadly), in that there is an over reliance on 
serendipity in the identification of new psychotropic compounds.  
 
3 
1.1.2.2 Device-Based Therapies 
Many novel invasive and non-invasive brain stimulation devices for treating depression under 
development, including transcranial magnetic stimulation, vagus nerve stimulation, and deep brain 
stimulation (Moreines, McClintock, & Holtzheimer, 2011). Such approaches are appealing 
because they offer the ability to focally target abnormal neural circuits (Ressler & Mayberg, 2007). 
Moreover, electroconvulsive therapy, at present the most widely used clinical tool for brain 
stimulation in depression, offers very high levels of efficacy in a fairly rapid time course (Kho, 
van Vreeswijk, Simpson, & Zwinderman, 2003). However, its use is limited by 
neuropsychological side effects, thought to be due to the lack of focality in the stimulation 
delivered to the brain (Sackeim et al., 2007).  
Deep brain stimulation emerged as a particularly exciting tool given the potential to focally 
target the treatment to highly localized brain regions and the high levels of success with using the 
approach in other neuropsychiatric diseases (Holtzheimer & Mayberg, 2011a).  However, despite 
success in early studies (Holtzheimer et al., 2012), many of the most promising investigational 
devices have encountered significant difficulties in late phase clinical trials.  Multiple reasons for 
these failures have been proposed (Widge, Deckersbach, Eskandar, & Dougherty, 2016), including 
a lack of consistently reliable means for identifying appropriate patients (Filkowski, Mayberg, & 
Holtzheimer, 2016; Riva-Posse, Holtzheimer, Garlow, & Mayberg, 2013), rush to complete 
clinical trials before reliable biomarkers to guide device implantation were identified (Riva-Posse 
et al., 2014),  and clinical trial designs that did not accurately predict and account for the extent of 
placebo response in highly treatment-resistant patients .  
Thus, despite significant efforts and excitement, there remain no commercially available 
device-based antidepressant approaches, aside from electroconvulsive therapy, that have 
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significantly greater antidepressant response likelihood or speed than traditional antidepressant 
medications.   
1.1.3 New Approach to Research: RDoC  
An examination of the status of medication development for depression, and psychiatric disorders 
more broadly, has identified a paucity in novel medication mechanisms as compared to other fields 
of medicine (Insel & Scolnick, 2006). Thus, despite an exponential increase in the number of 
medications now sold, many are just slight variations on existing compounds.  In the case of 
depression, and many other psychiatric disorders), it has become clear that the single diagnosis is 
in effect an amalgamation of many different diseases with a final common end point, and these 
subtypes likely require different approaches to treatment (Holtzheimer & Mayberg, 2011b). To 
help redirect research into novel treatments for psychiatric disorders, the NIMH created the 
Research Domain Criteria (RDoC), with the purpose of identifying specific domains of pathology 
within and across existing diagnoses, such as apathy or psychosis (Insel et al., 2010). The ultimate 
goal would be to assign classes of medications to the treatment of specific functional symptoms, 
as opposed to the existing research model of identifying a single medication to treat all aspects of 
a particular mental illness (O'Donnell & Ehlers, 2015). Such has been a successful approach in 
other fields of medicine such as cardiology, where heart failure is treated with a combination of 
agents that counteract the neurohumoral changes associated with the disease including beta 
blockers, angiotensin converting enzyme-inhibitors/angiotensin receptor blockers, diuretics, 
aldosterone antagonists, and other novel targets, each which are selected based on a defined set of 
factors including ejection fraction, fluid volume status, and functional class of disability (Yancy 
et al., 2016).   
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1.1.3.1 Positive Valence systems of the RDoC 
Within the RDoC construct, the Positive Valence Domain subcategory Approach Motivation is 
highly relevant to anhedonia, i.e. the lack of interest in previously pleasurable activities (NIMH 
RDoC Working Group, 2011). Moreover, the mesolimbic dopamine system is highly implicated 
in this process, suggesting that dopamine system dysfunction could be involved in the impairment 
in motivational and hedonic functions in MDD (Salamone & Correa, 2012). However, the 
relationship between the dopamine system and other brain regions with established roles in 
depression is currently poorly defined. We have identified that in other psychiatric disorders 
involving dopamine system dysfunction, the pathology is more a dysregulation of the dopamine 
system, rather than inherent pathology of the dopamine neurons themselves per se as is seen in 
neurodegenerative conditions such as Parkinson’s disease (Grace, 2016).  Thus, a better 
understanding is needed of how MDD circuit hubs influence dopamine system activity in normal 
and pathological states resembling MDD.  
1.1.4 Dopamine and Behavior 
Dopamine is a catecholamine tied to a wide variety of functional tasks ranging from movement, 
to motivation, to cognition depending on the pathway and site of its release (Bjorklund & Dunnett, 
2007). Contrasting results of nigrostriatal dopamine neuron dysfunction are Parkinson’s disease 
and Huntington’s disease, wherein diminished and enhanced dopamine neuron activation causes 
abnormally decreased and increased movement, respectively (S. D. Iversen & Iversen, 2007). In 
schizophrenia, over-activation of mesolimbic dopamine neurons has been tied to paranoia and 
psychosis (Kapur, 2003). Furthermore, all known drugs of abuse enhance dopamine release 
(Bonci, Bernardi, Grillner, & Mercuri, 2003). So diverse are the functions mediated by dopamine 
6 
that entire textbooks have been dedicated to this neurotransmitter (L. L. Iversen, Iversen, Dunnett, 
& Bjorklund, 2009). Thus for the purpose of this thesis, discussion is focused to elements of the 
dopamine system related to motivational dysfunction in depression. 
The role of dopamine in motivated behaviors is among the most fiercely debated topics in 
neuroscience. Among the earliest evidence for dopamine encoding motivationally relevant stimuli 
was the identification by Olds and Milner that stimulation of what was later identified to be the 
medial forebrain bundle resulted in highly reinforcing effects (Olds & Milner, 1954).  Later, in a 
seminal body of work dissecting cortico-limbic-striatal circuitry relevant to motivated behaviors, 
Mogenson argued that mesolimbic dopamine projections were a critical element of the circuit for 
the “translation from motivation into action” (Mogenson, Jones, & Yim, 1980). Wise then 
advanced the anhedonia hypothesis, based on evidence that neuroleptics that block dopaminergic 
transmission will prevent the acquisition of reinforced motivated behaviors (Wise, 1982). This 
notion was further evaluated by Berridge and Robinson, who argued for an incentive salience 
function of dopamine wherein dopamine does not mediate the experience of pleasure per se (i.e., 
“liking”), but rather its pursuit (i.e., “wanting”) (Berridge & Robinson, 1998). A slight 
modification of this theory was later proposed by Salamone and Correa, who delineated the 
appetitive and activational aspects of wanting, and demonstrated that the latter are more sensitive 
to disruption of dopaminergic transmission (Salamone & Correa, 2002). 
The above data were obtained primarily with interventions delivered before subjects 
interacted with the experimental stimuli (e.g. electrical stimulation or pharmacological blockade 
of dopamine pathways). However, a significant body of data also pertains to observing the effects 
of environmental stimuli on the firing responses of individual dopamine neurons as assessed with 
electrophysiology. This began after Schultz recorded from dopamine neurons in awake behaving 
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monkeys and observed that dopamine neurons tended to fire following the delivery of an 
unexpected reward (i.e. to signal a reward prediction error) (Schultz, Dayan, & Montague, 1997). 
This line of work has been continued in rodent models as well, particularly in computational and 
cognitive neuroscience circles, with significant interest in modeling dopamine neuron responses 
to given stimuli (Eshel et al., 2015).  
In individuals with depression, deficits tend to be present in both the mobilization to pursue 
reward, and the enjoyment of its delivery (Treadway & Zald, 2011). Thus, details of the circuitry 
driving both of these deficits need to be more clearly elucidated. 
1.1.5 Regulation of Dopamine Neuron Activity States 
Over the past four decades, an enormous amount has been learned about the cellular mechanisms 
governing the different activation states of dopamine neurons, how these firing patterns are 
regulated by afferent circuitry, and where this circuitry may be disrupted in disorders involving 
abnormal dopamine neuron function (Grace, 2016).   
1.1.5.1  Cellular Dynamics 
The mechanisms governing firing properties of dopamine neurons were characterized in a series 
of papers by Grace and Bunney using intracellular recording of dopamine neurons identified as 
such via histofluorescence (Grace & Bunney, 1980). Dopamine neurons exhibit a slow 
depolarizing pacemaker potential (Grace & Bunney, 1983a), which originates at the soma (Grace 
& Bunney, 1983b), and couples between adjacent cells (Grace & Bunney, 1983c). These neurons 
can show two types of firing: an irregular firing pattern of single spikes dependent on membrane 
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voltage and variable degrees of after hyperpolarization (Grace & Bunney, 1984b), and burst firing 
driven by calcium entry (Grace & Bunney, 1984a).  
However, not all neurons are spontaneously active, as some are in a non-firing state due to 
hyperpolarized membrane potentials (Grace & Bunney, 1983b). Only neurons that are exhibiting 
spontaneous spike activity are capable of transitioning to a burst mode, because burst firing is 
NMDA receptor dependent due to a calcium ion requirement (Chergui et al., 1993; Zweifel et al., 
2009), and NMDA receptors are impermeable to calcium when membranes are in hyperpolarized 
states due to blockade by magnesium (Mayer, Westbrook, & Guthrie, 1984). Thus, the number of 
spontaneously firing dopamine neurons serves as the gain in regulating the magnitude of the 
dopamine system’s phasic burst response to stimuli (Floresco, West, Ash, Moore, & Grace, 2003).  
1.1.5.2 Afferent Circuitry 
Further characterization of the different activity states of dopamine neurons has led to the 
discovery that different afferent circuits to the ventral tegmental area (VTA) regulate the number 
of spontaneously active dopamine neurons (i.e. dopamine population activity) and the amount of 
bursting occurring in these neurons (Lodge & Grace, 2006a). Burst firing is driven most potently 
by glutamatergic afferents from the pedunculopontine tegmentum (PPTg), gated by the 
laderodorsal tegmentum (Lodge & Grace, 2006b).  Population activity is regulated by GABAergic 
afferents, among the most proximal and potent being the ventral pallidum (VP), which serves as a 
converging point to distinct circuits that have been shown to increase or decrease dopamine 
population activity (Grace, 2016) (Figure 1).  
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Figure 1. Circuits Regulating Dopamine Neuron Population Activity and Bursting 
Polysynaptic circuits converging onto VP GABAergic afferents control the number of dopamine neurons that are 
spontaneously active, whereas the PPTg delivers glutamatergic signal that triggers burst firing. 
 
At baseline states in awake or anesthetized preparations, only half of dopamine neurons 
are depolarized enough to exhibit spontaneous firing (Chiodo & Bunney, 1985), whereas the 
remaining neurons are hyperpolarized by afferent GABAergic circuitry. When the strength of 
afferent inhibitory drive is modulated (either increased or decreased), there is a corresponding 
inverse change in the number of spontaneously active dopamine neurons (Grace, Floresco, Goto, 
& Lodge, 2007). This can be quantified by performing 6-12 tracks of extracellular recording and 
calculating the number of spontaneously active dopamine neurons encountered per electrode track 
searched, yielding the metric of cells per track (Bunney & Grace, 1978).  
10 
 Increased dopamine population activity occurs with activation of the ventral subiculum 
(vSub) of the hippocampus, which can be blocked when the glutamate antagonist kynurenic acid 
is infused into the NAc (Floresco, Todd, & Grace, 2001) or the GABA-A antagonist bicuculline 
is infused into the VP (Floresco et al., 2003). Together, these data suggest that the vSub drives an 
increase in dopamine population activity by enhancing NAc output, which is directed towards 
inhibition of the VP, thereby releasing more VTA dopamine neurons from VP inhibitory tone. 
Conversely, decreased dopamine population activity occurs with activation of the ILPFC, which 
can be blocked with kynurenic acid infusion in the BLA (Patton, Bizup, & Grace, 2013). BLA 
activation also reduces population activity, which is blocked by kynurenic acid infusion into the 
VP (Chang & Grace, 2014). This suggests that a circuit leading from the ILPFC through the BLA 
and VP inhibits dopamine population activity.  
1.1.6 Dopamine Circuitry in Animal Models  
The above circuits regulating dopamine neuron activity have been demonstrated to be highly 
relevant to animal models of psychiatric disorders involving increased or decreased dopamine 
system activity. The hyperdopaminergic state in schizophrenia has been studied using a 
neurodevelopmental model involving administration of the mitotoxin methazoxymethanol acetate 
(MAM) on day 17 of embryonic development (Moore, Jentsch, Ghajarnia, Geyer, & Grace, 2006). 
In this model, there is a marked increase in the number of spontaneously active dopamine neurons 
that is driven by pathological activation of the vSub (Lodge & Grace, 2007). In animal models 
employing chronic mild stress or amphetamine withdrawal, decreased dopamine neuron 
population activity has been identified, which is driven by heightened activation of the BLA 
(Belujon, Jakobowski, Dollish, & Grace, 2016; Chang & Grace, 2014). Collectively, these studies 
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in animal models of hyper and hypo dopaminergic states demonstrate the relevance of the circuits 
described above to disease states involving pathological changes in dopamine activity states.  
1.2 EVIDENCE FOR DOPAMINE DYSFUNCTION IN DEPRESSION 
The involvement of the dopamine system in MDD has been a focus of significant research effort 
in both clinical samples and animal models of depression. A selection of particularly important 
advances in both arenas are reviewed below.  
1.2.1 Human Studies 
Anhedonia is a core symptom of MDD (American Psychiatric Association, 2013) and is believed 
to be strongly tied to dysfunction of the dopamine system (Treadway & Zald, 2011). 
Measurements of dopamine metabolites in depressed patients showing reduced cortical dopamine 
turnover suggest tonic dopamine release in decreased in depression (Lambert, Johansson, Agren, 
& Friberg, 2000). Behavioral measurements of reward deficits in depression have found that 
patients show reduced capacity for acquiring rewarded behaviors (Pizzagalli, Iosifescu, Hallett, 
Ratner, & Fava, 2008). Using fMRI blood flow changes as a proxy measure for neuronal 
activation, studies of patients with MDD suggest dampened striatal responses to delivery of reward 
(Pizzagalli et al., 2009) or recollection of positive memories (Keedwell, Andrew, Williams, 
Brammer, & Phillips, 2005), which correlate with self-reported levels of anhedonia. Reduced 
responses in these regions also occur in trait anhedonia in subjects without MDD, suggesting that 
reductions in this pathway may mediate reward deficits more broadly (Gorwood, 2008). 
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Furthermore, healthy individuals demonstrate reduced striatal blood flow changes to reward when 
exposed to psychological stress while performing reward-based tasks (Kumar et al., 2014).  Thus, 
in line with the RDoC, it has been suggested that examining the relationship between dopamine 
system dysfunction and anhedonia as a function of stress exposure across diagnoses could yield 
promising information (Pizzagalli, 2014). 
 
1.2.2 Animal Studies 
The first use of chronic stress to induce a depressive-like state in rodents was performed by Katz 
et al, in which rats were subjected to a 21-day period of persistently varied severe daily stressors 
including foot shock, forced swim in iced bath, prolonged (46-hour) food or water deprivation, tail 
pinch, shaker stress, and novel cage mates (Katz, Roth, & Carroll, 1981). This procedure was 
found to result in a number of clinically relevant behavioral deficits reminiscent of MDD including 
anxiety in an open field and reduced consumption of sucrose or saccharine solution, which were 
responsive to the tricyclic antidepressant imipramine  (Katz, 1982) or electroconvulsive therapy 
(Katz, 1981). This procedure was later revised by Willner et al who observed that similar deficits 
could be obtain with far milder intensity stressors including changes in lighting, white noise, damp 
bedding, and shorter duration (22-hour) food and water deprivation (Willner, Muscat, & Papp, 
1992), so long as the stressors were varied and unpredictable (Muscat & Willner, 1992).  
 From an early stage in the use of CMS, there was interest in the role of dopamine in driving 
anhedonic behavioral effects. Dopamine agonists were found to acutely reverse anhedonic like 
behavioral deficits (Willner et al., 1992), as were antidepressants targeting the dopamine system 
such as bupropion . More recently Tye et al demonstrated that optogenetic activation of VTA 
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dopamine neurons could reverse behavioral deficits induced by CMS (Tye et al., 2013). Thus, 
there is a clear role for dopamine system activation in ameliorating CMS-induced deficits in 
depressive-related behaviors.  
1.2.2.1 Conflicting Evidence From Different Animal Models 
The direction of change in dopamine activity became a topic of debate recently due to seemingly 
opposing results obtained using distinct animal models of depression (A. Grace & Moreines, 
2014). The chronic social defeat (CSD) model of depression was originally developed in rats and 
adapted to mice (Miczek, Yap, & Covington, 2008). CSD involves subjecting an “intruder” mouse 
to exposure to a larger “resident” mouse in its home cage, which results in the intruder mouse 
being attacked by the larger resident mouse. This procedure is repeated daily for 10 days, after 
which the intruder mouse shows behavioral deficits relevant to depression including reduced 
sucrose preference and social interaction (Berton et al., 2006). In this model, a finding that appears 
to be critical to the behavioral phenotype is an increase in firing rate of VTA dopamine neurons 
(Cao et al., 2010). In contrast, rats exposed to the CMS or learned helplessness (LH) models of 
depression show reductions in the number of spontaneously active dopamine neurons, but not 
changes in dopamine neuron firing rates or bursting (Belujon & Grace, 2014; Chang & Grace, 
2014). 
The issue of differences in the apparent role of dopamine between the CSD and CMS 
depression peaked when two conflicting articles were published together in Nature showing that 
optogenetic activation of dopamine neurons enhanced the effects of CSD (Chaudhury et al., 2013), 
but reversed the effects of CMS (Tye et al., 2013), on depressive-related behaviors. To reconcile 
these differences, one must consider the distinct roles of dopamine in the induction vs. expression 
of depression. Acutely, severe stressors such as restraint stress activate the DA system (Valenti, 
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Lodge, & Grace, 2011), consistent with Chaudhury et al. (2013) who reported that increased DA 
neuron phasic activity during chronic social defeat stress (CSDS) was necessary for induction of 
the depressive phenotype that follows (Chaudhury et al., 2013). Thus, the initial increase in 
dopamine observed during and immediately after stress drives downstream plasticity, ultimately 
resulting in depression. In contrast, 24 hours after stress (e.g. acute restraint), there is a shift in the 
opposite direction, i.e. a reduction in dopamine neuron population activity (Chang & Grace, 2013). 
This is consistent with Tye et al. (2013), who observed that after CMS, phasic activation of 
dopamine neurons drove recovery from the depressive phenotype.  Thus, in time, the dopamine 
up-regulation converts to down-regulation, and this hypoactivity causes depression-related 
behaviors (Belujon & Grace, 2014; Chang & Grace, 2014). Until recently, it was unclear whether 
CSDS caused this same overall down-regulation of the DA system. This question was indirectly 
addressed when the Chaudhury et al. group published in Science that activation of DA neurons 
long after CSDS has an antidepressant effect (Friedman et al., 2014), suggesting hypoactivation 
of the DA system may be present in the CSDS depression model as well. A second, related issue 
is that methodological differences in DA recording techniques between the CSDS studies and our 
findings preclude a direct comparison of the two lines of inquiry. CSDS has been demonstrated to 
increase firing rate of individual DA neurons (Krishnan et al., 2007), whereas its impact on the 
population activity of the DA system has not been assessed. 
1.3 CLINICALLY IDENTIFIED NODES FOR INVESTIGATION 
The work by Chang and Grace (2014) identified the BLA and VP as critical nodes in the 
downregulation of dopamine population activity after CMS. For the first portion of this thesis, we 
15 
examine additional brain regions with potential to be involved in the CMS-induced 
hypodopaminergic circuit (Figure 2) based on a synthesis of clinical and basic science literature 
discussed below. 
 
Figure 2. Established and Potential Nodes in CMS Circuit 
Chang and Grace (2014) identified the BLA and VP as driving down VTA dopamine neuron population activity 
following CMS. Other clinically relevant targets including BA25 and LHb have not yet been examined for 
involvement in this model. 
 
1.3.1 BA25/ILPFC 
1.3.1.1 Human Studies 
There is strong evidence for altered function of BA25 in MDD based on a large number of brain 
imaging studies of patients with depression in both resting and active states (Mayberg, 2003). 
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BA25 activity decreases with depression treatment, and increases with induction of sad mood in 
healthy individuals or remitted patients (Goldapple et al., 2004; Mayberg et al., 1999). One 
explanation for this could be that BA25 has decreased volume in familial MDD due to loss of 
inhibitory neuropil (Ongur, Drevets, & Price, 1998), potentially contributing to the fact that a 
metabolic increase in this region in seen in MDD patients only after accounting for the decrease 
in tissue volume. Furthermore, BA25 is also well poised to be part of a network of limbic structures 
with well documented involvement in MDD such as the amygdala and hippocampus, thus making 
it an attractive potential target for deep brain stimulation therapy for intractable MDD (Mayberg, 
2009).  
1.3.1.2 Animal Studies 
The rodent homologue of BA25 has been determined to be the ILPFC based on overlapping 
projections revealed in comparative anatomical study of rodents and nonhuman primates 
(Heilbronner, Rodriguez-Romaguera, Quirk, Groenewegen, & Haber, 2016). In rodent studies, 
inhibiting ILPFC astrocytic glutamate uptake induces anhedonia (John et al., 2012). Importantly, 
activation of the ILPFC in normal animals potently reduces the number of spontaneously active 
dopamine neurons, in a BLA-dependent manner (Patton et al., 2013). However, this prior study 
did not examine medial-lateral differences in dopamine neuron inhibition within the VTA, or the 
contributions of the ILPFC to the reduction in spontaneously active dopamine neurons after CMS.   
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1.3.2 Lateral Habenula 
1.3.2.1 Human Studies 
Despite rapidly increasing interest in the region, the LHb at present has comparatively less data 
available from human studies (Boulos, Darcq, & Kieffer, 2016). Early studies showed that 
inducing depressive symptoms in remitted major depression patients via tryptophan depletion 
increased LHb metabolism measured by PET (Morris, Smith, Cowen, Friston, & Dolan, 1999). 
MR imaging data from the LHb is sparse, attributable to the difficulty with imaging a structure of 
that size (i.e. less than a few smoothed voxels) and location (i.e. adjacent to pulsatile CSF flow), 
however modern advances in MR physics and signal acquisition protocols have allowed new 
studies of this region to be possible (Lawson, Drevets, & Roiser, 2013; Lawson et al., 2014). Data 
acquired with this new approach in patients with MDD did not show tonic changes in LHb activity, 
but did reveal diminished responses to aversive stimuli (Lawson et al., 2016). The most compelling 
clinical evidence for LHb involvement in MDD comes from cases where deep brain stimulation 
was applied to the lateral habenula with modest improvements in clinical status (Kiening & 
Sartorius, 2013). 
1.3.2.2 Animal Studies 
The LHb has potent inhibitory projections to the VTA (Christoph, Leonzio, & Wilcox, 1986) both 
directly and indirectly through the rostromedial tegmentum (RMTg), which is the major inhibitory 
relay connecting the LHb with the VTA (Balcita-Pedicino, Omelchenko, Bell, & Sesack, 2011). 
In studies of awake behaving nonhuman primates, firing of LHb neurons and VTA DA neurons 
appear to be anticorrelated, with VTA DA neurons firing with receipt of reward and LHb neurons 
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firing with omission of expected reward, implicating the LHb as a “disappointment signal” 
(Hikosaka, 2010).  
There is a large amount of animal model data on the LHb, primarily using the learned 
helplessness rodent model of depression.  Volumetric increases in the LHb have been observed in 
rats bred for increased susceptibility to learned helplessness (Henn & Vollmayr, 2005), and 
increased firing rate has been observed in LHb neurons that project directly to the VTA (B. Li et 
al., 2011). Reducing afferent drive selectively in the LHb by manipulating protein kinase 
expression was found to ameliorate helplessness (K. Li et al., 2013).  
1.4 PHARMACOLOGICAL TARGETING OF DOPAMINE  
As knowledge has increased regarding the alterations in the dopamine system in MDD, so too has 
interest in exploring the utility of dopaminergic medications for its treatment. Interestingly, 
amphetamine, which elevates tonic dopamine release via vesicle unloading and reuptake 
inhibition, has not been found to be significantly helpful as an antidepressant (Satel & Nelson, 
1989), other than improving concentration in patients where this is impaired (Reus, Silberman, 
Post, & Weingartner, 1979). However, the norepinephrine and dopamine reuptake inhibitor 
(NDRI) bupropion is a very useful antidepressant medication (Zung, 1983), particularly in patients 
with anhedonia (Nutt et al., 2007), and is approved for use in MDD. Thus, there is a clear role for 
medications that act on the dopamine system in the treatment of MDD, and greater understanding 
of the effects of these medications will help guide future efforts to optimize their use in the clinical 
arena.  
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1.4.1 Evidence for Quetiapine in MDD 
The antidepressant effect of quetiapine was initially identified in studies of its use for 
schizophrenia (Mullen, Jibson, & Sweitzer, 2001). It was then formally evaluated as monotherapy 
for bipolar depression in two clinical trials in which it was found to be effective, at lower doses 
than in schizophrenia (i.e. 300-600 mg/day vs 800 mg/day) (Calabrese et al., 2005; Thase et al., 
2006). Quetiapine was next evaluated in patients with unipolar depression, in which it was shown 
to be effective when used in the augmentation of a SSRI or SNRI (Bauer et al., 2009; McIntyre, 
Gendron, & McIntyre, 2007) or as monotherapy at 150-300 mg/day (Cutler et al., 2009), with 
optimal results at 300 mg/day when used as augmentation (El-Khalili et al., 2010) and 150 mg/day 
when used as monotherapy (Weisler et al., 2009).  In addition, maintenance of therapy in patients 
who experienced remission with quetiapine treatment markedly reduced the risk of depression 
relapse over the ensuing 1-year follow-up period (Liebowitz et al., 2010).   
1.4.2 Antipsychotic drugs effects on dopamine neurons 
Upon the discovery that APDs functioned as D2RAs, there was immediate significant interest in 
identifying the effects of these medications on firing properties of dopamine neurons. There are 
four decades of history of examining the effects of antipsychotic drugs on the dopamine system. 
1.4.2.1 Acute Effects of APDs 
The original studies of the effects of D2RAs on dopamine neuron firing properties were performed 
in the nigra following administration of haloperidol. This resulted in an acute increase in the 
number of spontaneously active dopamine neurons (Bunney & Grace, 1978). It was determined 
that there are two predominant mechanisms driving the increase in observed dopamine neuron 
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activity with APDs (Grace, Bunney, Moore, & Todd, 1997). The first is the blockade of D2 
autoreceptors on presynaptic terminals, which is most associated with acute changes in firing rate 
of dopamine neurons since the somatodendritic D2 autoreceptors are the primary determinant of 
dopamine neuron firing rate (Bunney & Grace, 1978). The second is the blockade of post-synaptic 
D2 receptors, and the resultant increase in feedback excitatory drive from the striatum to the VTA 
via direct and indirect circuits, as lesioning of these feedback pathways prior to D2RA treatment 
blocks the increase in dopamine neuron population activity (Bunney & Grace, 1978).  
The effects of acute treatment with other D2RA agents were found to be similar to 
haloperidol (Chiodo & Bunney, 1983), with the notable exception that for second generation 
D2RAs the increase in dopamine neuron population activity was isolated to the A10 (VTA) region, 
whereas for haloperidol it was observed in both the A9 (nigra) and A10 regions (Skarsfeldt, 1995). 
The mechanism for this may involve non-dopamine receptor effects of the medications (Chiodo & 
Bunney, 1985). 
1.4.2.2 Chronic Effects of APDs 
When quetiapine was administered as repeated treatment for 28 days at a low dose (10 mg/kg), the 
number of spontaneously active dopamine neurons returned to baseline levels (Skarsfeldt, 1995). 
However, when administered at higher doses (20-40 mg/kg), quetiapine was found to decrease the 
number of spontaneously active dopamine neurons (Skarsfeldt, 1995), via induction of 
depolarization block (Goldstein, Litwin, Sutton, & Malick, 1993).  
1.4.2.3 D2RA Treatment in Animal Models of Psychiatric Disorders 
It has been observed that the effects of D2RA treatment in an animal model of schizophrenia are 
different than their effects in normal rats. Specifically, in normal rats, D2RAs require repeated 
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administration for >21 days in order to induce depolarization block (Bunney & Grace, 1978). 
However, in the MAM model, D2RAs induce depolarization block after the first dose (Valenti, 
Cifelli, Gill, & Grace, 2011). Thus there is reason to expect that the effects of D2RA treatment 
may also differ from that of controls in rats exposed to the CMS model of depression, which 
involves a markedly hypodopaminergic state. If quetiapine treatment were to normalize dopamine 
population activity after CMS, this would be expected to contribute to its antidepressant effect. 
1.5  GOALS OF DISSERTATION RESEARCH 
1.5.1 Circuit Goals 
Given the evidence for the involvement of the ILPFC and LHb in depression we sought to 
characterize the effects on the dopamine system of modulating activity in these regions in normal 
and CMS-exposed rats. Based on our preliminary data, our hypothesis was that both ILPFC and 
LHb would inhibit dopamine neuron population activity when activated in normal rats, but that 
the ILPFC was the primary driver of the CMS-induced deficit in dopamine population activity.  
1.5.2 Pharmacology Goals 
Given the evidence that D2RAs can increase dopamine population, activity we wondered if the 
documented antidepressant effect of quetiapine could involve a dopaminergic mechanism. Despite 
extensive literature on the mechanisms of quetiapine’s antipsychotic effect in the context of 
schizophrenia, little is known about its antidepressant mechanism. Furthermore, most existing 
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theories center not on quetiapine itself, but rather its metabolite N-Desalkyl quetiapine that acts as 
a reuptake inhibitor of norepinephrine. Because rats do not naturally produce this metabolite 
(Cross et al., 2016), the isolated effects of the quetiapine could be examined in our rodent model. 
Thus, we administered quetiapine in acute and repeated dosing to CMS-exposed rats in order to 
attempt to elucidate a possible contribution of its D2RA properties to its antidepressant 
mechanism.  
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2.0  INVOLVEMENT OF INFRALIMBIC PREFRONTAL CORTEX BUT NOT 
LATERAL HABENULA IN DOPAMINE ATTENUATION  
AFTER CHRONIC MILD STRESS 
Moreines, J.L., Owrutsky, Z.L., & Grace, A.A. Select role for infralimbic cortex but not habenula 
in dopamine attenuation after chronic mild stress. Neuropsychopharmacology (In Press) 
 
2.1 INTRODUCTION 
Depression has been classically associated with dysfunction within the serotonin system, based 
primarily on the mode of action of antidepressant drugs (Carlsson, 1976).  However, acutely 
increasing serotonin levels fails to alleviate symptoms, and antidepressant drugs require 8-12 
weeks of treatment to be efficacious (Ressler & Nemeroff, 2000).  In contrast, dopamine system 
dysfunction contributes to two key characteristics of depression: anhedonia (Treadway & Zald, 
2011) and amotivation (Salamone & Correa, 2012).  As a consequence, the dopamine system has 
garnered increasing attention for its role in depression (Nestler & Carlezon, 2006).   
Dopamine neurons can fire in two distinct patterns, a spontaneous irregular tonic pattern 
and a more selectively recruited phasic burst pattern, the latter proposed to be the salient output of 
the system signaling behaviorally relevant stimuli (Grace & Bunney, 1984a, 1984b).  Because 
dopamine neurons must be spontaneously active to burst fire, the amount of baseline tonic activity 
represents the gain, or level of amplification, of the phasic response (Lodge & Grace, 2006a), with 
tonic firing regulated by a polysynaptic circuit leading to the ventral pallidum (Grace et al., 2007).  
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In psychiatric disorders, aberrant functioning of this afferent control system is the more common 
source of dopamine system dysfunction, rather than a primary pathology of the dopamine neurons 
per se (Grace, 2016).  
Using two distinct animal models of depression, we have recently demonstrated deficits in 
tonic dopamine neuron activity, expressed as reduced population activity of ventral tegmental area 
(VTA) dopamine neurons (Belujon & Grace, 2014; Chang & Grace, 2014). Moreover, we 
identified critical involvement of the ventral pallidum and basolateral amygdala in driving the 
reduced dopamine neuron population activity observed in rats exposed to the chronic mild stress 
(CMS) rodent depression model (Chang & Grace, 2014).  
A recent surge of clinical and translational research has identified multiple additional 
circuit nodes potentially involved in depression-related dopamine system dysregulation. 
Brodmann Area 25 (BA25) is homologous with the rodent infralimbic prefrontal cortex (ILPFC) 
(Heilbronner et al., 2016) and is widely considered to be a critical hub in depression neurocircuitry 
(Drevets, 1999; Mayberg, 2003). Nearly any form of therapeutically effective treatment for 
depression is associated with reversal of hypermetabolism in BA25 (Mayberg, 2009). In recent 
studies of normal rodents, activating ILFPC reduced dopamine neuron activity (Patton et al., 2013) 
as well as downstream network effects throughout the striatum that correlated with diminished 
reward-seeking behavior (Ferenczi et al., 2016). However, these experiments did not employ 
depression animal models.  
The lateral habenula (LHb) has also garnered attention for a possible role in depression 
(Hikosaka, 2010). Clinical data on the LHb are limited owing to its difficulty to image (Lawson et 
al., 2013); however, it has shown promise as a target for deep brain stimulation for intractable 
depression (Sartorius et al., 2010). Interest in the region emerged primarily from its role in the 
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learned helplessness (LH) model of depression (Henn & Vollmayr, 2005; B. Li et al., 2011). When 
activated acutely, the LHb potently inhibits dopamine neuron firing (Ji & Shepard, 2007) and 
induces a transient aversive state (Stamatakis & Stuber, 2012) due to reduced synaptic dopamine 
levels (Hikosaka, Sesack, Lecourtier, & Shepard, 2008). However, the impact of persistent LHb 
activation on the population activity of dopamine neurons has not been assessed in normal rats or 
in depression animal models.  
In the present study, we characterized the impact of ILPFC and LHb activation on 
dopamine neuron firing properties in normal rodents, and each region’s involvement in the 
dopamine neuron inhibition induced by CMS. We found that ILPFC and LHb activation have 
divergent effects on dopamine neuron firing properties. Furthermore, only ILPFC inactivation 
following CMS was capable of restoring normal dopamine system activity levels.   
2.2 METHODS 
2.2.1 Subjects 
All experiments were performed using adult male Sprague-Dawley rats (Envigo, Indianapolis, 
Indiana) weighing ≥300g, housed in pairs in a temperature- (22°C) and humidity- (47%) controlled 
colony room (lights ON 7:00AM-7:00PM) with food and water available ad libitum, and 
acclimated to the facilities for 7 days. All procedures were performed in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved 
by the Institutional Animal Care and Use Committee of the University of Pittsburgh. 
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2.2.2 CMS Procedure 
Animals receiving CMS were single-housed in individual cages within a dedicated room.  CMS 
was delivered as previously described (Chang & Grace, 2014).  Stressors – delivered in the home 
cage – included periodic restricted access to food and water, cage tilt, damp bedding, continuous 
overnight illumination, intermittent paired housing with an unfamiliar cage-mate, white noise (80-
90db), stroboscopic lighting, and predator odor. Each week, 3-4 stressors were delivered in a novel 
combination. 
2.2.3 Behavioral Assays 
The full behavioral impact of our CMS procedure has been detailed previously (Chang & Grace, 
2014). Thus, for the present study, only behaviors necessary to verify the CMS effect were 
assessed. Animals housed on a reverse light cycle were weighed weekly.  At the conclusion of 
CMS, animals were tested for immobility on the Forced Swim Test (FST).  Due to differences in 
sensitivity and behavioral profile of different rodent strains, we have found that the sucrose 
preference test is not a reliable indicator of dopamine system function specifically in Sprague-
Dawley rats (Chang & Grace, 2014), unlike other strains such as Lister Hooded, Long-Evans, or 
Wistar (Tye et al., 2013; Weiss, 1997; Willner, Lappas, Cheeta, & Muscat, 1994; Willner et al., 
1992). 
2.2.3.1  FST Procedure 
The FST was performed following an established protocol (Slattery & Cryan, 2012) over two 
sequential days during the dark cycle, using plastic cylinder tubes (50 cm height; 20cm diameter) 
27 
filled to 30cm with water (23-25°C).  On day 1, the rat was placed in the water for 15 minutes in 
order to eliminate nonspecific behaviors. On day 2 (24hrs later), the rat was placed in the water 
for 5 minutes, and its behavior was captured by video for offline blinded scoring.  The total time 
the rat spent immobile on day 2 was tabulated as an index of behavioral despair. 
2.2.4 Electrophysiological Recordings 
2.2.4.1 Surgery 
Electrophysiological recordings were performed with light cycle counterbalanced across 
experimental groups. Rats were anesthetized with chloral hydrate (400mg/kg; i.p.), placed in a 
stereotaxic frame (David Kopf Instruments, Tujunga, CA), and maintained at 37°C using a 
thermocouple-controlled heating pad (Fine Science Tools, Foster City, CA). The skull was cleared 
of skin and fascia, and a partial craniectomy was performed to access the VTA and ILPFC or LHb 
using the following target coordinates referenced from bregma: VTA -5.3-5.7mm posterior, +0.6-
1.0 mm lateral, and -6.5-9.5mm ventral (to brain surface); ILPFC +3.2mm anterior, +0.5mm 
lateral, and -5.0mm ventral; LHb -3.6mm posterior, +0.8mm lateral, and -5.5mm ventral. 
2.2.4.2 Drug Delivery 
Microinfusions of drugs were delivered to the ILPFC or LHb using a 28-gauge stainless steel 
cannula (Plastics One, Roanoake, VA) as described previously (Patton et al., 2013). All drugs were 
dissolved in Dulbecco’s phosphate buffered saline (dPBS; Sigma Aldrich, St. Louis, MO) as 
vehicle (VEH). N-methyl-d-aspartate (NMDA; Sigma Aldrich, 0.75μg NMDA/0.5μL dPBS) was 
used for activation, and tetrodotoxin (TTX; Sigma Aldrich, 1μmol/L) was used for inactivation, 
based on previous data establishing the neural effects of these dosages (Floresco et al., 2001; Patton 
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et al., 2013). Infusion concentration was consistent for all regions, while volume was adjusted for 
brain region size (0.5μL for ILPFC; 0.25μL for LHb) and infused at a rate of 0.25μL/min (total 
infusion time 2 min for ILPFC, 1 min for LHb). The cannula was left in place >5 min following 
infusion to allow for adequate diffusion.  
2.2.4.3 VTA Single Unit Recordings 
Twenty minutes following drug microinfusion into LHb or ILPFC, single unit electrophysiological 
recordings of identified VTA dopamine neurons were performed.  Single barrel electrodes  were 
constructed from 2mm diameter borosilicate capillary tubes (World Precision Instruments, 
Sarasota, FL) using a vertical electrode puller (Narishige, Tokyo, Japan), broken to a target of 6-
10MΩ under microscopic control, and filled with 2% Chicago Sky Blue (Sigma Aldrich) dissolved 
in 2M saline.  Signal was acquired using an amplifier (Fintronics, Orange, CT) with open filter 
settings (50Hz low cutoff, 16kHz high cutoff, 1000x gain) and displayed on an oscilloscope (B&K 
Precision, Yorba Linda, CA) with signal fed to a computer running Lab Chart 7 (AD Instruments, 
Sidney, Australia). Units were recorded when signal-to-noise ratio exceeded 3:1. 
2.2.4.4 Dopamine Neuron Identification 
Electrodes were lowered into the VTA using a manual hydraulic microdrive (Kopf Instruments) 
and dopamine neurons were identified using well established criteria including location, slow, 
irregular firing pattern, and long duration, variable shape biphasic action potential waveform 
(>2.2msec) and half-width (>1.1msec) (Grace & Bunney, 1983a; Ungless & Grace, 2012) (Figure 
3). Each dopamine neuron identified was recorded for 3 minutes (1 minute minimum). Three 
parameters of dopamine neuron firing were calculated: 1) the number of dopamine neurons 
identified in each track (i.e. population activity averaged over 9 tracks), 2) firing rate, and 3) 
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proportion of spikes occurring as burst firing (%SIB) in which the burst onset was defined as two 
spikes with ≤80msec interspike interval and termination by >160msec interspike interval (Grace 
& Bunney, 1984a). 
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Figure 3. Examples of Neurons Identified as Dopamine and Non-Dopamine 
A) Sample trace of dopamine neuron recording demonstrating key action potential features including long duration and biphasic ascending phase.  B) 
Sample recording of VTA dopamine neuron showing characteristic irregular, slow firing rate, mixed with sporadic periods of burst firing. C) Sample 
trace of a neuron identified as non-dopaminergic. Note the short duration action potential. D) Sample recording of a VTA neuron identified as non-
dopaminergic. Note the comparatively more regular firing pattern. 
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2.2.4.5 VTA Sampling 
The VTA was sampled in 9 sequential electrode tracks separated by 0.2mm and arranged in a 
predetermined grid pattern to assess the distribution of dopamine neuron activity across the medial-
lateral extent of the A10 region (Figure 1E). The “Medial” dopamine neurons targeted in this paper 
include those located in the lateral-most aspects of the Interfascicular (IF) and Central Linear (CL) 
nuclei and medial aspect of the Paranigral (PN) nucleus. “Central” VTA sampled mostly from the 
PN nucleus and the medial aspect of the Parabrachial Pigmented (PBP) area. “Lateral” VTA 
centered on the lateral-most aspects of the PBP area. This procedure was developed to sample 
dopamine neurons with a variety of different projection targets (Ikemoto, 2007), and has been 
published by us in multiple prior studies (Valenti, Gill, & Grace, 2012; Valenti, Lodge, et al., 
2011). In order for a rat to be included in the final sample, data must have been available from all 
three VTA locations (i.e. medial, central, and lateral). 
Figure 4. Location of VTA Recording Tracks 
Locations of medial (M), central (C), and lateral (L) subregions of VTA. Blue dot in lateral track indicates the depth 
at which dopamine neurons were found in this animal. 
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2.2.5 Histology 
At the conclusion of recordings, final electrode placement was marked by electrophoretic ejection 
of dye. Rats were then overdosed with additional chloral hydrate, decapitated, and brains removed. 
Brains were fixed in 8% paraformaldehyde followed by 25% sucrose for cryoprotection, sectioned 
using a cryostat (Leica, Buffalo Grove, IL) into 60 micrometer coronal slices, mounted onto 
gelatin-chromalum coated glass slides, and stained with cresyl violet and neutral red in order to 
check placements of recording electrodes and infusion cannulae tips. Extent of drug diffusion from 
ILPFC and LHb microinfusions was estimated from pilot infusions of an identical volume of 
fluorescent muscimol (TMR-X BODIPY, Fisher, Waltham, MA; Figure 5). To ensure adequate 
and repeatable VTA sampling across animals, rats were excluded if VTA tracks were: 1) not 
observed laterally beyond the IF and CL nuclei, 2) located lateral to the PBP (i.e. encroaching on 
the substantia nigra), or 3) only visible anterior to the PN or posterior to the PBP nucleus. 
Figure 5. Estimating Diffusion of Infused Drugs 
Fluorescent microscope image from infusion of fluorescently tagged marker into ILPFC used to estimate diffusion of 
subsequent drug microinfusions 
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2.2.6 Data Analysis 
Individual neuron data was analyzed by Lab Chart to identify spike time courses and exported to 
Neuroexpolorer (Nex Technologies, Madison, AL) to calculate firing rate and burst firing. 
Population activity (i.e. cells per track; CPT) was averaged within each animal followed by across 
animals in each group, whereas neuron firing rate and burst activity were averaged across animals 
in a group, considering each cell as an independent replicate.  Data were analyzed using SPSS 23 
(IBM, Armonk, NY). All data sets were compared to the normal Gaussian distribution using the 
Kolmogorov-Smirnov and Shapiro-Wilk tests. Data sets that deviated from the normal distribution 
were analyzed with Mann-Whitney U or Kruskal-Wallis H followed by Dunn’s post-hoc tests as 
appropriate. Normally distributed data were analyzed using independent sample two-tailed t-tests 
or ANOVA followed by Tukey’s post-hoc tests as appropriate. 
2.3 RESULTS 
2.3.1 Normal Rats 
2.3.1.1 ILPFC Activation 
ILPFC activation by local infusion of NMDA markedly reduced the number of spontaneously 
active VTA dopamine neurons recorded per electrode track (VEH 1.1 ± 0.12 CPT, n=8; NMDA 
0.76 ± 0.038 CPT, n=11; t8.4=2.4, p=0.040; Figure 6A), consistent with prior studies (Patton et al., 
2013). ILPFC activation also induced a small but significant increase in average burst firing (VEH 
21.6 ± 3.2 %SIB, n=68; NMDA 27.7 ± 3.2 %SIB, n=61; U=2.12, p=0.034; Figure 6F). No change 
34 
in average firing rate was observed (VEH 3.4 ± 0.26 Hz, n=68; NMDA 3.3 ± 0.23 Hz, n=61; 
U=0.307, p=0.76; Figure 6C).  
Given evidence that the VTA is functionally segregated (Ikemoto, 2007), the data were 
analyzed according to location in medial, central, or lateral VTA. Population activity was 
profoundly reduced in medial VTA (VEH 1.3 ± 0.12 CPT, n=8; NMDA 0.65 ± 0.15 CPT, n=11; 
t17=3.4, p=0.0037; Figure 6B), but not affected significantly in central and lateral portions, (2way 
ANOVA Location x Drug interaction, F(2, 34)=3.35, p=0.047). In contrast, elevated bursting was 
found to be isolated to neurons in lateral VTA (VEH 20.5 ± 6.7 %SIB, n=18; NMDA 39.0 ± 5.4 
%SIB, n=16; U=2.48, p=0.012; Figure 6G; Table 1). The frequency distribution of bursting for 
these neurons suggested that ILPFC activation drove a previously non-bursting population (i.e. 
zero %SIB) into a higher bursting state (Figure 6H). ILPFC activation did not alter average 
dopamine neuron firing rate, either overall or in any VTA subregion (Figure 6D; Table 1). 
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Figure 6. Activation of ILPFC inhibits dopamine population activity 
ILPFC activation selectively attenuated dopamine neuron population activity in the medial aspects of the VTA.  A) 
Dopamine neuron population activity was reduced following microinfusion of NMDA into the ILPFC. B) This effect 
was significant only in medial VTA. C-E) Average firing rate of identified dopamine neurons was not different 
between animals that received VEH infusions vs. NMDA.  F) Average amount of bursting activity in identified 
dopamine neurons was increased in animals that received ILPFC vs. VEH.  G) This occurred via a select increase in 
bursting activity in dopamine neurons located in lateral VTA. H) Examination of the histograms of lateral VTA 
dopamine neuron bursting levels for each infusion group suggested that NMDA drove lateral VTA dopamine neurons 
from a typically non-bursting state (i.e. 0 %SIB) into one in which more neurons showed moderate levels of bursting. 
I) Location of NMDA (dark red circles) and VEH (light red circles) infusions into ILPFC. *p<0.05; **p<0.01 
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Table 1. Summary of Dopamine Neuron Data Following ILPFC Activation 
 
  
 VEH NMDA p-value 
Cells Per Track    
   All VTA 1.1 ± 0.12 0.76 ± 0.038 t=2.4, p=0.040 
     Medial 1.3 ± 0.12 0.65 ± 0.15 t=3.4, p=0.0037 
     Central 0.98 ± 0.21 1.0 ± 0.13 t=-0.28, p=0.78 
     Lateral 0.85 ± 0.15 0.58 ± 0.088 t=1.7, p=0.11 
    
Firing Rate (Hz)    
   All VTA 3.4 ± 0.26 3.3 ± 0.23 U=0.307, p=0.76 
     Medial 3.2 ± 0.41 3.6 ± 0.40 U=1.3, p=0.18 
     Central 3.9 ± 0.47 2.9 ± 0.36 U=-1.5, p=0.13 
     Lateral 3.0 ± 0.49 3.6 ± 0.46 U=1.2, p=0.25 
    
Bursting (%SIB)    
   All VTA 21.6 ± 3.2 27.7 ± 3.2 U=2.12, p=0.034 
     Medial 19.6 ± 4.9 21.5 ± 5.3 U=1.3, p=0.21 
     Central 25.5 ± 5.7 25.5 ± 5.2 U=0.055, p=0.96 
     Lateral 20.5 ± 6.7 39.0 ± 5.4 U=2.5, p=0.012 
    
Group Size  (Rats) N=8 N=11  
   All VTA (Cells) N=68 N=61  
     Medial (Cells) N=29 N=20  
     Central (Cells) N=21 N=25  
     Lateral (Cells) N=18 N=16  
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2.3.1.2 LHb Activation 
Local infusion of NMDA into the LHb caused a marked reduction in dopamine neuron population 
activity (VEH 1.0 ± 0.087 CPT, n=10; NMDA 0.68 ± 0.070 CPT, n=12; t20=3.1, p=0.0053; Figure 
7A) along with a modest increase in average VTA dopamine neuron firing rate (VEH 3.3 ± 0.24 
Hz, n=73; NMDA 4.1 ± 0.25 Hz, n=69; U=2.6, p=0.008; Figure 7C). There was no change in 
average amount of burst activity (VEH 26.2 ± 3.0 %SIB, n=73; NMDA 26.3 ± 2.9 %SIB, n=69; 
U=0.58, p=0.56; Figure 7F).  
In marked contrast to the ILPFC, LHb activation potently and selectively decreased 
population activity of lateral VTA dopamine neurons, inducing a 70% decrease (VEH 0.88 ± 0.12 
CPT, n=10, NMDA 0.26 ± 0.063 CPT, n=12; t20=4.9, p=0.000092; Figure 7B). Moreover, LHb 
activation induced a 39% increase in firing rate of medially located VTA dopamine neurons (VEH 
3.3 ± 0.24 Hz, n=29; NMDA 4.7 ± 0.36 Hz, n=32; U=2.8, p=0.005; Figure 7D). Bursting was 
unaffected in all VTA subregions (Figure 7G; Table 2).  
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Figure 7. Activation of Lateral Habenula in Normal Rats 
LHb activation selectively attenuated dopamine neuron population activity in the lateral aspects of the VTA.  A) 
Dopamine neuron population activity was reduced following infusion of NMDA into the LHb. B) This occurred via 
selective reduction in lateral VTA dopamine neuron population activity. C) Average firing rate of identified dopamine 
neurons was higher in NMDA-infused rats vs. VEH. D-E) This effect was driven by a selective increase in the average 
firing rate of dopamine neurons located in medial VTA following NMDA infusion in LHb. F-H) No changes occurred 
in average amount of dopamine neuron bursting activity following infusion of NMDA. I) Location of NMDA (closed 
blue circles) and VEH (open blue circles) infusions into LHb. **p<0.01; ****p<0.0001 
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Table 2. Dopamine Neuron Data Following LHb Activation 
 
 
 
  
 VEH NMDA p-value 
Cells Per Track    
   All VTA 1.0 ± 0.087 0.68 ± 0.70 t=3.1, p=0.0053 
     Medial 1.1 ± 0.15 0.89 ± 0.15 U=-1.2, p=0.25 
     Central 1.1 ± 0.15 0.90 ± 0.16 U=-0.98, p=0.35 
     Lateral 0.88 ± 0.12 0.26 ± 0.063 t=-4.9, p=0.000092 
    
Firing Rate (Hz)    
   All VTA 3.3 ± 0.24 4.1 ± 0.25 U=2.6, p=0.008 
     Medial 3.3 ± 0.47 4.7 ± 0.36 U=2.8, p=0.005 
     Central 3.2 ± 0.30 3.6 ± 0.35 U=0.55, p=0.58 
     Lateral 3.5 ± 0.47 4.0 ± 0.80 t=-0.58, p=0.57 
    
Bursting (%SIB)    
   All VTA 26.2 ± 3.0 26.3 ± 2.9 U=0.58, p=0.56 
     Medial 30.0 ± 5.6 25.9 ± 4.5 U=0.17, p=0.86 
     Central 20.4 ± 4.8 26.0 ± 3.9 U=1.4, p=0.16 
     Lateral 27.7 ± 4.8 28.9 ± 11.8 U=-3.8, p=0.71 
    
Group Size  (Rats) N=10 N=12  
   All VTA (Cells) N=73 N=69  
     Medial (Cells) N=29 N=32  
     Central (Cells) N=24 N=29  
     Lateral (Cells) N=20 N=8  
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2.3.2 Chronic Mild Stress 
In order to determine the relevance of ILPFC and LHb activity to dopamine system hypofunction 
in an animal model of depression, the regionally specific effects of CMS on VTA dopamine neuron 
firing, and how this compares with the impact of ILPFC and LHb activation, were assessed.  
 
2.3.2.1 Vehicle Infused Rats 
Following CMS, animals showed increased FST immobility (CON 173.4 ± 23.38 sec, n=8, CMS 
233.3 ± 9.91 sec, n=8, t14=2.36, p=0.037; figure S1a) and reduced body weight gain (2-way 
ANOVA Group x Time Interaction F(5, 36) = 3.7, p=0.0078; figure S1b), consistent with prior 
studies (Chang & Grace, 2014). CMS-exposed rats exhibited >50% fewer spontaneously active 
VTA dopamine neurons (CON-VEH 1.3 ± 0.091 CPT, n=12, CMS-VEH 0.62 ± 0.049 CPT, n=14; 
H=22.4, p<0.0001; Figure 8A), with no change in dopamine neuron firing rate (CON-VEH 3.8 ± 
0.18 Hz, n=125, CMS-VEH 3.7 ± 0.24 Hz, n=82; H=6.0, p=0.11; Figure 8C) or bursting (CON-
VEH 31 ± 2.4 %SIB, CMS-VEH 28 ± 2.9 %SIB, H=2.9, p=0.40; Figure 8F), also consistent with 
prior studies (Chang & Grace, 2014).  When examined with regard to VTA subregions, CMS-
exposed rats showed 67% reductions in dopamine neuron population activity in medial VTA 
(CON-VEH 1.5 ± 0.13 CPT, n=12, CMS-VEH 0.55 ± 0.084 CPT, n=14; H=21.3, p<0.0001; Figure 
8B) and 50% in central VTA (CON-VEH 1.4 ± 0.17 CPT, n=12, CMS-VEH 0.77 ± 0.10 CPT, 
n=14; H=14.5, p=0.012; Figure 8B), whereas lateral VTA was not significantly impacted (CON-
VEH 0.92 ± 0.16 CPT, n=12, CMS-VEH 0.53 ± 0.10 CPT, n=14; H=10.2, p=0.12; Figure 8B). No 
changes were observed following CMS in average dopamine neuron firing rate or bursting activity 
in any VTA subregion (Figure 8C-H; Table 3). 
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2.3.2.2 ILPFC or LHb Inactivation 
TTX infusion into the ILPFC of CMS-exposed rats also normalized dopamine neuron population 
activity in medial (CON-VEH 1.5 ± 0.13 CPT, n=12, CMS-ILPFC-TTX 1.1 ± 0.14 CPT, n=10; 
H=6.6, p>0.99) and central (CON-VEH 1.4 ± 0.17 CPT, n=12, CMS-ILPFC-TTX 1.1 ± 0.16 CPT, 
n=10; H=6.2, p=0.77) VTA to levels comparable to control animals (Figure 8B). A concurrent 
small reduction in average firing rate of medial dopamine neurons was observed (CON-VEH 3.8 
± 0.27 Hz, n=50, CMS-ILPFC-TTX 2.6 ± 0.27 Hz, n=28; H=20.8, p=0.023), possibly due to the 
emergence of a new population of slow-firing dopamine neurons in medial VTA following TTX 
infusion into the ILPFC (Figure 8C-E).  TTX infusion into the LHb exerted no effect on VTA 
dopamine neuron population activity or firing parameters in CMS-exposed rats in any subregion 
of the VTA (Figure 8; Table 3).  These data demonstrate a critical role for ILPFC in CMS-induced 
reductions in dopamine neuron population activity. 
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Figure 8. Inactivation of ILPFC or LHb Following Chronic Mild Stress 
Only ILPFC inactivation restored VTA dopamine neuron activity in CMS-exposed rats.  A) Rats that underwent CMS showed lower VTA dopamine neuron 
population activity compared to rats housed in CON conditions. Inactivation of ILPFC using microinfusion of TTX restored normal dopamine neuron population 
activity whereas inactivation of LHb using microinfusion of TTX had no impact on VTA dopamine neuron population activity. B) The reduction in VTA dopamine 
neuron population activity following CMS was greatest in Medial and Central VTA subregions, while no significant change in dopamine population activity was 
observed in Lateral VTA.  Inactivation of the ILPFC using TTX resulted in normalization of dopamine neuron population activity in Medial and Central VTA 
subregions. C-D) While VTA-wide average dopamine neuron firing rates did not differ between groups, a select reduction in the average firing rate of dopamine 
neurons located in medial VTA was observed in CMS-TTX-ILPFC rats compared to CON. E) The histogram of medial VTA dopamine neuron firing rates suggests 
an increase in the number of dopamine neurons firing at a slower rate following TTX microinfusion into the ILPFC in CMS-exposed rats. F-H) No changes in 
amount of bursting activity in identified dopamine neurons occurred in any group or VTA subregion.  I-J) Location of microinfusions for CON-VEH (grey circles), 
CMS-VEH (light red and blue circles), CMS-TTX-ILPFC (dark red circles), and CMS-TTX-LHb (dark blue circles). *p<0.05; ***p<0.001; ****p<0.0001 
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    Table 3. Summary of Dopamine Neuron Data from CMS Experiment 
 CON-VEH  CMS-VEH  
 Mean ± 
SEM 
ap-value  Mean ± 
SEM 
bp-value 
Cells Per Track      
   All VTA 1.3 ± 0.091 H=31.3, p<0.0001  0.62 ± 0.049 H=22.4, p<0.0001 
     Medial 1.5 ± 0.13 H=25.4, p<0.0001  0.55 ± 0.084 H=21.3, p<0.0001 
     Central 1.4 ± 0.17 H=13.1, p=0.0045  0.77 ± 0.10 H=14.5, p=0.012 
     Lateral 0.92 ± 0.16 H=10.5, p=0.015  0.53 ± 0.10 H=10.2, p=0.12 
      
Firing Rate (Hz)      
   All VTA 3.8 ± 0.18 H=6.0, p=0.11  3.7 ± 0.24 c- 
     Medial 3.8 ± 0.27 H=7.9, p=0.049  4.0 ± 0.46 H=0.90, p>0.99 
     Central 3.9 ± 0.30 H=2.2, p=0.53  3.7 ± 0.38 c- 
     Lateral 3.4 ± 0.38 H=2.3, p=0.51  3.3 ± 0.45 c- 
      
Bursting (%SIB)      
   All VTA  30.8 ± 2.4 H=2.9, p=0.40  27.5 ± 2.9 c- 
     Medial 26.2 ± 3.7 H=4.3, p=0.23  26.7 ± 5.3 c- 
     Central 33.1 ± 3.9 H=1.5, p=0.68  30.5 ± 4.8 c- 
     Lateral 23.3 ± 4.8 H=29, p=0.40  22.9 ± 4.9 c- 
      
Group N (Rats) N=12 -  N=14  - 
   All VTA (Cells) N=125 -  N=82 - 
     Medial (Cells) N=50 -  N=25 - 
     Central (Cells) N=47 -  N=34 - 
     Lateral (Cells) N=28 -  N=23 - 
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Table 3 (continued). 
  CMS-TTX-ILPFC  CMS-TTX-LHb 
 Mean ± 
SEM 
bp-value  Mean ± 
SEM 
bp-value 
    
 1.1 ± 0.078 H=3.9, p>0.99 0.57 ± 0.057 H=24.4, p<0.0001 
 1.1 ± 0.14 H=6.6, p>0.99 0.50 ± 0.090 H=22.2, p<0.001 
 1.1 ± 0.16 H=6.2, p=0.77 0.65 ± 0.11 H=17.8, p=0.0062 
 1.0 ± 0.10 H=-4.7, p>0.99  0.56 ± 0.12 H=8.8, p=0.38 
      
      
 3.1 ± 0.18 c-  3.8 ± 0.40 c- 
 2.6 ± 0.27 H=20.8, p=0.023  3.9 ± 0.89 H=4.3, p>0.99 
 3.4 ± 0.37 c-  3.3 ± 0.59 c- 
 3.2 ± 0.30 c-  4.4 ± 0.68 c- 
      
      
 25.3 ± 2.8 c-  28.7 ± 4.4 c- 
 21.3 ± 4.0 c-  26.4 ± 8.0 c- 
 32.1 ± 5.5 c-  25.3 ± 7.1 c- 
 23.5 ± 4.5 c-  36.3 ± 7.9 c- 
      
 N=10 -  N=8 - 
 N=83 -  N=40 - 
 N=28 -  N=11 - 
 N=28 -  N=15 - 
 N=27 -  N=14 - 
 
aKruskal-Wallis test for all groups;  
bDunn’s post-hoc test vs. CON-VEH group; 
cNo post-hoc performed because Kruskal-Wallis p>0.05 
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2.4 DISCUSSION 
In this study, activation of either the ILPFC or the LHb in normal animals reduced the population 
activity of VTA dopamine neurons (i.e. the number of dopamine neurons spontaneously active). 
Whereas ILPFC activation exerted a greater inhibitory effect on medial VTA dopamine neurons, 
the LHb selectively inhibited lateral VTA dopamine neurons (Figure 9). In rats exposed to CMS, 
the reduction in dopamine neuron population activity was preferential to medial and central VTA. 
ILPFC inactivation restored dopamine neuron population activity to a normal level, whereas LHb 
inactivation did not affect this parameter.  
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Figure 9. One Potential Circuit Diagram Proposed to Account for ILPFC and LHb Regulation of Dopamine 
Neuron Population Activity in Normal and Stressed States 
In the normal state, afferent regions are functioning at baseline levels, leading to baseline levels of VTA dopamine 
neuron population activity. When activated, the ILPFC preferentially inhibits dopamine neurons located in medial 
VTA, which tend to project more to the reward- and motivation-related areas of the nucleus accumbens, whereas the 
LHb preferentially inhibits dopamine neurons located in lateral VTA, which project more to cognitive/decision related 
dorsomedial striatal regions [See Ikemoto (2007), Figure 12 for review of anatomy]. CMS involves ILPFC-driven 
inhibition of dopamine neurons, as its inactivation restored normal levels of dopamine neuron population activity 
  
48 
 
Following some of the manipulations, in addition to changes in population activity, there 
were also small but significant changes in firing rate and bursting. We have reported previously 
that DA neurons must be spontaneously active to respond to behaviorally relevant, phasic inputs 
(Floresco et al., 2003; Lodge & Grace, 2006a). Therefore, a change in population activity better 
reflects the responsivity of the system, and is altered in several disease states (Grace, 2016).  ILPFC 
activation in normal rats reduced dopamine population activity medially but increased the 
tendency of lateral neurons to burst fire. Because the majority of dopamine neurons in medial VTA 
project to accumbens shell, reducing the active number would be expected to markedly reduce the 
response of ventromedial accumbens-projecting DA neurons to reward-related stimuli (Grace, 
2016) since only spontaneously active dopamine neurons are capable of responding to signals with 
burst firing. This may underlie the reduced motivation for reward in depressed individuals, as 
Ferenczi et al (2016) showed activation of the ILPFC induced depression-related behavior in 
normal rats that was associated with functional connectivity changes between the ILPFC and 
ventral striatum. In contrast, the increased tendency to burst fire was observed in lateral VTA 
dopamine neurons, which project more strongly to associative striatum, although the number of 
spontaneously active neurons did not change. Although speculative, this tonic change in bursting 
could reflect changes in plasticity with respect to the salience of environmental stimuli, 
contributing to the well-documented affective bias and hypersensitivity to negative valence stimuli 
and feedback in depression (Clark, Chamberlain, & Sahakian, 2009).  
Following CMS, inactivation of the ILPFC restored the number of spontaneously active 
dopamine neurons to normal levels, while reducing the average firing rate of medial dopamine 
neurons, due to an increase in the number of slower firing dopamine neurons (Figure 8E). While 
49 
changes in firing rate may engender a change in baseline DA levels in the accumbens, the impact 
on responsivity to stimuli would be comparatively minimal and likely to undergo homeostatic 
compensation.   
Intriguingly, ILPFC inactivation in CMS-exposed rats restored normal dopamine 
population activity in both medial and central VTA, while ILPFC activation in normal rats 
inhibited only medial VTA population activity. In normal rats, ILPFC inactivation increases 
dopamine neuron population activity through indirect activation of the ventral subiculum of the 
hippocampus via the nucleus reunions (Patton et al., 2013; Zimmerman & Grace, 2016). Thus, 
inhibition of ILPFC in the CMS-exposed rats in the present paper (or inhibition of BA25 in patients 
with depression such as via DBS) may engage distant downstream brain networks that together 
work to restore normal dopamine-mediated hedonic functions via a mechanism that may differ 
from simple reversal of abnormal plasticity per se.  
LHb activation in normal rats reduced dopamine population activity laterally but increased 
firing rate medially. Inhibition of lateral dopamine neurons has been shown to alter reward 
expectation and decision-making (Eshel, Tian, Bukwich, & Uchida, 2016), supporting a role for 
LHb-mediated inhibition of these neurons impacting cognitive tasks (Stopper & Floresco, 2014). 
Conversely, the small increase in medial dopamine neuron firing rate with LHb activation likely 
reflects a known, small, monosynaptic glutamatergic projection from the LHb to cortically 
projecting dopamine neurons in medial VTA (Lammel et al., 2012). Although this di-synaptic 
projection was shown to be aversive functionally (assessed by conditioned place avoidance), 
increased activity of cortically-projecting dopamine neurons has actually been shown to be 
protective against developing depression (Chaudhury et al., 2013). In CMS-exposed rats, LHb 
inactivation had no effect. Importantly, LHb activation has previously been shown to be aversive 
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(Stamatakis & Stuber, 2012), but never to be pro-depressive in normal animals (i.e. without a 
genetic predisposition to helplessness). Moreover, recent neuroimaging data questions whether 
heightened LHb activity actually drives responses in depressed humans (Lawson et al., 2016).  
These results add to the accumulating evidence supporting a major role of the dopamine 
system in stress and depression. Dopamine lesions, antagonists, or direct optogenetic attenuation 
of dopamine neurons reduces reward pursuit similar to that seen in depressed patients with 
anhedonia, whereas rats that have received CMS show a reversal of behavioral despair by 
optogenetic activation of VTA dopamine neurons (Tye et al., 2013).  While this may at first appear 
inconsistent with studies using the chronic social defeat (CSD) model, in which dopamine system 
activation facilitates defeat-mediated depression (Chaudhury et al., 2013), this may have more to 
do with the relative timing of the interventions.  Thus, in each of the studies with CMS or LH, 
dopamine neuron activity was measured >24 hours after removal of the stressor.  In contrast, 
activation of accumbal-projecting dopamine neurons with social defeat during the induction phase  
increased the susceptibility of mice to defeat-induced depression, consistent with an established 
role for these neurons in acute stress (Valenti, Lodge, et al., 2011).  These collective data are highly 
consistent with a model in which stress-induced dopamine neuron activation is followed by a much 
longer attenuation of dopamine neuron activity, as has been observed 24 hours after dopamine 
system activation by restraint (Chang & Grace, 2013) or amphetamine (Belujon et al., 2016), and 
following chronic cold stress (Moore, Rose, & Grace, 2001; Valenti et al., 2012). This is consistent 
with Koob’s opponent process model, in which dopamine activation is followed by a long-duration 
compensatory attenuation of the dopamine system (Koob, Stinus, Le Moal, & Bloom, 1989). Thus, 
we observed the decrease in dopamine neuron activity following withdrawal of LH or CMS 
(Belujon & Grace, 2014; Chang & Grace, 2014), and Tye et al (2013) found that VTA dopamine 
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neuron activation reversed the impact of CMS following withdrawal of the stressor, which was 
later replicated in the CSD depression model as well (Friedman et al., 2014).  
In summary, the current data highlight distinct roles for the ILPFC and LHb in regulating 
VTA dopamine neurons in normal and chronic stress-exposed states.  If this translates to major 
depressive disorder in humans, this also would provide a target site for therapeutic intervention 
within the ILPFC/BA25 to normalize dopamine neuron drive.  
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3.0  DIVERGENT EFFECTS OF ACUTE AND REPEATED QUETIAPINE 
TREATMENT ON DOPAMINE SYSTEM IN NORMAL AND  
CHRONIC MILD STRESS INDUCED HYPODOPAMINERGIC STATES 
Moreines JL, Owrutsky ZL, Gagnon, KG, Grace AA. Divergent Effects of Acute and Repeated 
Quetiapine Treatment on Dopamine System in Normal and Chronic Mild Stress Induced 
Hypodopaminergic States. In Preparation. 
3.1 INTRODUCTION 
Quetiapine and other second-generation dopamine (DA) D2 receptor antagonists (D2RA), e.g. 
lurasidone, are increasingly popular monotherapy and as an adjunct to antidepressant drugs in 
patients with inadequate responses to traditional antidepressants alone (Saunders & Goodwin, 
2013). However, the therapeutic mechanism of these agents in depression is largely unknown. For 
quetiapine specifically, existing theories highlight the role of a drug metabolite N-Desalkyl 
quetiapine, which functions as a potent norepinephrine reuptake inhibitor (Chernoloz, El Mansari, 
& Blier, 2012). However, this model does not incorporate the D2RA properties of quetiapine.  
Mounting evidence suggests that in depression the dopamine system is underactive 
(Belujon & Grace, 2015; Grace, 2016). Thus, it is important to reconcile how a compound that is 
thought to block dopamine transmission may actually help a condition that results from already 
reduced dopamine system function. Importantly, existing theories are based on data from 
administering quetiapine to normal rats, whereas the effect of quetiapine on the dopamine system 
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in rodent depression models has not been examined. However, as has become clear in other settings 
such as animal models of schizophrenia, the effects of D2RAs on a normally functioning dopamine 
system often differ substantially from their effects on a dopamine system functioning in a 
pathological state (Valenti, Cifelli, et al., 2011). It is therefore critical to examine the impact of 
quetiapine on animal models of depression that exhibit clinically relevant pathological functioning 
of the dopamine system.  
Dopamine neurons fire in two patterns, spontaneous firing and burst firing (Grace et al., 
2007). In order to burst fire a neuron must already be spontaneously active. We have recently 
reported that across multiple animal models of depression, including chronic mild stress (CMS) 
(Moreines, Owrutsky, & Grace, 2016) and learned helplessness (Belujon & Grace, 2014), the 
number of spontaneously active dopamine neurons is markedly reduced without changes to their 
firing rate or amount of burst firing. In the CMS model specifically, we have further elucidated 
that this decrease in dopamine population activity following exposure to chronic stress is due to 
enhanced afferent GABA-ergic input from the ventral pallidum driving dopamine neurons into a 
silent state, as inactivation of this region restores dopamine population activity to normal levels 
(Chang & Grace, 2014).  
Multiple studies across animal models (Tye et al., 2013) and human patients with 
depression (Schlaepfer, Bewernick, Kayser, Madler, & Coenen, 2013) have suggested that 
restoring normal dopamine system function could be a valuable approach to treating depression, 
particularly in cases with prominent dopamine related symptoms such as anhedonia. Thus, if 
quetiapine were to increase the population activity of dopamine neurons, this would be expected 
to contribute to its antidepressant effect. While the effects of quetiapine on the dopamine system 
have been extensively studied in normal rodents, the effects of quetiapine on the dopamine system 
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in animal models of depression has not been studied. Specifically, acute administration of 
quetiapine at antidepressant doses has been shown to increase dopamine population activity 
(Goldstein et al., 1993), whereas after repeated administration dopamine neuron population 
activity is at baseline or lower levels (Skarsfeldt, 1995).  However, behavioral studies using the 
CMS model suggest that quetiapine may have the ability to reverse deficits in behavioral assays 
relevant to depression, specifically when administered at the lower antidepressant-level dose of 10 
mg/kg for long durations (Orsetti et al., 2007). This suggests that the effects of repeated quetiapine 
may differ in the presence of factors driving a hypodopaminergic state, e.g. chronic stress.  
In the present study, we evaluated the acute and repeated treatment effects of an 
antidepressant dosage of quetiapine in both normal and CMS-exposed rats. We find that repeated 
quetiapine administration produces strikingly different effects in normal vs. stressed rodents. 
3.2 METHODS 
3.2.1 Subjects 
All procedures were performed in accordance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee of the University of Pittsburgh. 
Adult male Sprague-Dawley rats (Envigo, Indianapolis, Indiana) weighing ≥300g were 
used for all experiments. They were acclimated to the facilities for >7 days, housed in pairs in a 
temperature- (22°C) and humidity- (47%) controlled colony room (lights ON 7:00AM-7:00PM). 
Food and water were available ad libitum.  
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3.2.2 CMS Procedure 
CMS was performed as reported previously (Chang & Grace, 2014; Moreines et al., 2016). CMS 
exposed rats were single-housed in individual cages within an isolated colony room. Stressors 
included periodic restricted access to food and water, cage tilt, damp bedding, continuous 
overnight illumination, intermittent paired housing with an unfamiliar cage-mate, white noise (80-
90db), stroboscopic lighting, and predator odor, all delivered in the home cage. Each week, 3-4 
stressors were delivered in a novel combination. 
3.2.3 Drug Preparation 
Quetiapine 10 mg/mL was dissolved in 0.3% tartaric acid in physiological saline and neutralized 
with sodium hydroxide to a final pH of 5-6. This dose (10 mg/kg) was selected based on prior 
studies showing electrophysiological (Goldstein et al., 1993) and behavioral (Orsetti et al., 2007) 
effects at this dose. Vehicle treated rats received 1 ml/kg injections of the same solution without 
the addition of quetiapine; the two solutions were equivalent in pH and temperature.   
3.2.4 Electrophysiological Recordings 
3.2.4.1 Surgery 
Electrophysiological recordings were performed during the light phase. Rats anesthetized with 
chloral hydrate (400mg/kg; i.p.) were placed in a stereotaxic frame (David Kopf Instruments, 
Tujunga, CA) and maintained at 37°C using a thermocouple-controlled heating pad (Fine Science 
56 
Tools, Foster City, CA). To access the VTA, the skull was cleared of skin and fascia, and a partial 
craniectomy of the skull was performed 5.3-5.7mm posterior and +0.6-1.0 mm lateral to bregma.  
3.2.4.2 Signal Acquisition 
Single barrel electrodes were constructed with a vertical electrode puller (Narishige, Tokyo, Japan) 
using 2mm diameter borosilicate capillary tubes (World Precision Instruments, Sarasota, FL), and 
then broken to a target of 6-10MΩ under microscopic control and filled with a 2M saline solution 
with 2% Chicago Sky Blue (Sigma Aldrich).  Signals were fed through silver wire to an amplifier 
(Fintronics, Orange, CT) operated with open filter settings (50Hz low cutoff, 16kHz high cutoff, 
1000x gain), displayed on an oscilloscope (B&K Precision, Yorba Linda, CA), and stored on a 
computer running Lab Chart 7 (AD Instruments, Sidney, Australia). Units were recorded when 
signal-to-noise ratio exceeded 3:1.   
3.2.4.3 VTA Sampling and Dopamine Neuron Identification 
The VTA was sampled over a grid of 9 sequential electrode tracks separated by 0.2mm and 
arranged in a predetermined pattern to reliably sample across the medial-lateral and anterior-
posterior extent of the A10 region. Electrodes were lowered into the VTA using a manual hydraulic 
microdrive (Kopf Instruments) and dopamine neurons were identified using well established 
criteria including location, slow, irregular firing pattern, and long duration, variable shape biphasic 
action potential waveform (>2.2msec) and half-width (>1.1msec) (Grace & Bunney, 1983a; 
Ungless & Grace, 2012). Identified dopamine neurons were recorded for 3 minutes (1 minute 
minimum), and three parameters of dopamine neuron firing were calculated: 1) the number of 
spontaneously firing dopamine neurons identified in each track (i.e. population activity averaged 
over 9 tracks), 2) firing rate, and 3) proportion of spikes occurring as burst firing (%SIB) in which 
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the burst onset was defined as two spikes with ≤80msec interspike interval and termination by 
>160msec interspike interval (Grace & Bunney, 1984a). 
3.2.5 Experimental Outline 
The experiments performed are outlined in Figure 10. 
 
 
Figure 10. Experimental Timeline of CMS QTP 
In Experiments 1 and 2, rats experienced 5-7 weeks of CMS or control conditions. This was followed by acute 
administration of quetiapine on the day of dopamine neuron recording (Experiment 1) or 21+ days of quetiapine up 
to the day of dopamine neuron recording (Experiment 2). In Experiment 3, rats living in normal housing conditions 
received 21+ days of quetiapine up to the day of dopamine neuron recording, which included measurements of 
dopamine neuron population activity before and immediately following a pre-synaptic dose of apomorphine. 
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3.2.5.1 Acute quetiapine in normal and CMS-exposed rats 
Rats were exposed to 5-7 weeks of CMS or control conditions. On the day of dopamine neuron 
recording, quetiapine was administered 2 hours prior to beginning the recording.  
3.2.5.2 Repeated quetiapine in normal and CMS-exposed rats 
Rats were exposed to 5 weeks of standard CMS or control conditions, followed by an additional 
3+ weeks during which they received daily injections of quetiapine 10 mg/kg or vehicle in parallel 
with the CMS protocol. Electrophysiological recordings began 2 hours following the final dose.  
3.2.5.3 Repeated quetiapine plus apomorphine in normal rats 
Rats received daily injections of quetiapine 10 mg/kg for >21 days, which is a standard minimum 
duration for the induction of depolarization block (Grace et al., 1997). Electrophysiological 
recordings were performed beginning 2 hours after the final dose. A recording of VTA population 
activity was performed. Apomorphine dissolved in normal saline (50 mcg/mL) was then delivered 
intravenously at autoreceptor-selective dosages via the lateral tail vein until a decrease in firing 
rate of >20% was observed, with most rats showing response with 40-80 g/kg, consistent with 
prior studies (Valenti, Cifelli, et al., 2011). The VTA was then resampled for population activity. 
These recordings were counterbalanced across animals for anteroposterior starting location within 
the VTA.  
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3.2.6 Histology 
Final electrode placement at the conclusion of recording was marked by electrophoretic ejection 
of Pontamine dye. Rats were overdosed with additional chloral hydrate and decapitated. Brains 
were removed and fixed in 8% paraformaldehyde followed by 25% sucrose for cryoprotection. 
Sixty micrometer coronal sections were prepared using a cryostat (Leica, Buffalo Grove, IL), 
mounted onto gelatin-chromalum coated glass slides, and stained with cresyl violet and neutral red 
for microscopic confirmation of recording electrode location.  
3.2.7 Data Analysis 
Spike time courses for individual neurons were exported from Lab Chart into Neuroexpolorer (Nex 
Technologies, Madison, AL) for calculation of firing rate and burst firing. Within each rat, 
population activity was calculated by dividing the total number of dopamine neurons identified by 
the number of valid tracks performed, yielding the metric of Cells Per Track (CPT). The average 
firing rate and amount of burst activity for dopamine neurons recorded were averaged across rats 
in a group, considering each cell as an independent replicate. Data were analyzed in SPSS 23 
(IBM, Armonk, NY) and Prism 7 (GraphPad, La Jolla, CA). For experiments 1 and 2, 2-way 
ANOVAs with post-hoc tests were performed to compare treatment groups. For experiment 3, 
paired t-tests were performed to compare data collected before and after apomorphine 
administration. 
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3.3 RESULTS 
3.3.1 Experiment 1: Acute quetiapine increased dopamine neuron population activity in 
normal rats but not chronically stressed rats 
The differential effect of acute quetiapine in normal and stress exposed rats was evaluated by 
administering an acute dose of quetiapine (10 mg/kg) 2 hours prior to assessing VTA dopamine 
neuron firing properties. This resulted in a significant interaction effect between treatment with 
acute quetiapine and exposure to CMS for dopamine population activity (2-way ANOVA 
interaction F(1,25)=4.3, p=0.049, Figure 11, Table 4). Acute administration of quetiapine to normal 
rats increased dopamine population activity (CON-VEH-Acute 1.1 ± 0.11 CPT, n=8; CON-QTP-
Acute 1.4 ± 0.068 CPT, n=11; 2-way ANOVA interaction F(1,25)=4.3, p=0.049; post-hoc t25=3.3, 
p=0.0054; Figure 11A, Table 4), in line with prior reported results (Goldstein et al., 1993). There 
was no change in the average firing rate of recorded dopamine neurons (CON-VEH-Acute 4.4 ± 
0.30 Hz, n=69; CON-QTP-Acute 3.5 ± 0.23 Hz, n=120; 2-way ANOVA p>0.05 for main effects 
of drug or interaction; Figure 11B-D, Table 4) or proportion of burst activity (CON-VEH-Acute 
33.9 ± 3.6 %SIB, n=69; CON-QTP-Acute 25.0 ± 2.4 %SIB, n=120; 2-way ANOVA p>0.05 for 
main effects of drug or interaction; Figure 11E-G, Table 4).  
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Figure 11. Impact of Acute Quetiapine Treatment in Normal and Chronically Stressed Rats 
Acute administration of quetiapine increased dopamine population activity in normal rats, but had no effects on CMS-
exposed rats. A) Dopamine population activity was increased following acute administration of quetiapine to normal 
rats, but the reduction observed in stressed rats was not ameliorated by acute administration. B-G) Average dopamine 
neuron firing rate (B-D) and proportion of burst firing (E-G) were unchanged by acute administration of quetiapine to 
normal or CMS-exposed rats.   
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Table 4. Summary of Dopamine Neuron Data for Acute Quetiapine 
 
 
 
 
 
 
 
 
 
 
 
aMain effects among all groups;  
bSidak’s post-hoc test for drug effect (within same stress category); 
cSidak’s post-hoc test for stress effect (within same drug group); 
dMain effect not significant, post-hoc test not performed 
 CON-VEH-Acute CON-QTP-Acute CMS-VEH-Acute CMS-QTP-Acute 
Cells Per Track 1.1  0.11 1.4  0.068 0.47  0.11 0.45  0.019 
Interaction F(1,25) = 4.3 ; p = 0.049a - - - 
Drug F(1,25) = 3.3; p = 0.081a t(25) = 3.3; p = 0.0054b - t(25) = 0.15; p = 0.99b 
Stress F(1,25) = 72.6; p < 0.0001a - t(25) = 4.2; p = 0.0006c t(25) = 8.3; p < 0.0001c 
     
Firing Rate (Hz) 4.4  0.30 3.5  0.23 3.7  0.30 3.4  0.31 
Interaction F(1,227) = 0.46 ; p = 0.50a - - - 
Drug F(1,227) = 2.6; p = 0.11a -d - -d 
Stress F(1,227) = 0.94; p = 0.33a - -d -d 
     
Bursting (%SIB) 33.9  3.6 25.0  2.4 29.9  6.1 23.2  4.7 
Interaction F(1,227) = 0.056 ; p = 0.81a - - - 
Drug F(1,227) = 2.8; p = 0.094a -d - -d 
Stress F(1,277) = 0.39; p = 0.53a - -d -d 
     
Group N (Rats) N = 8 rats, 69 cells N = 11 rats, 120 cells N = 4 rats, 19 cells N = 6 rats, 23 cells 
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In line with prior results, CMS-exposed rats treated acutely with vehicle had fewer 
spontaneously active dopamine neurons as compared to control rats treated acutely with vehicle 
(CON-VEH-Acute 1.1 ± 0.11 CPT, n=8; CMS-VEH-Acute 0.47 ± 0.11 CPT, n=4; 2-way ANOVA 
main effect of stress F(1,25)=72.6; p < 0.0001; post-hoc t25=4.2, p=0.0006; Figure 11A, Table 4), 
without a change in firing rate (CON-VEH-Acute 4.4 ± 0.30 Hz, n=69; CMS-VEH-Acute 3.7 ± 
0.30 Hz, n=19; 2-way ANOVA p>0.05 for main effects of stress or interaction; Figure 11B-D, 
Table 4) or proportion of burst activity (CON-VEH-Acute 33.9 ± 3.6 %SIB, n=69; CMS-VEH-
Acute 29.9 ± 6.1 %SIB, n=19; 2-way ANOVA p>0.05 for main effects of stress or interaction; 
Figure 11E-G, Table 4).  
In contrast to the effect observed in normal rats, quetiapine had no effect on dopamine 
neuron population activity in CMS-exposed rats (CMS-VEH-Acute 0.47 ± 0.11 CPT, n=6; CMS-
QTP-Acute 0.45 ± 0.019 CPT; post-hoc t25=0.15, p=0.99; Figure 11A, Table 4). Similarly, there 
was no effect on average dopamine neuron firing rate (CMS-VEH-Acute 3.7 ± 0.30 Hz, n=19; 
CMS-QTP-Acute 3.4 ± 0.31 Hz, n=23; 2-way ANOVA p>0.05; Figure 11B-D, Table 4), or 
proportion of burst activity (CMS-VEH-Acute 29.9 ± 6.1 %SIB, n=19; CMS-QTP-Acute 23.2 ± 
4.7 %SIB, n=23; 2-way ANOVA p>0.05; Figure 11E-G, Table 4).   
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3.3.2 Repeated Quetiapine Alters Dopamine Activity in Stressed Rats but not Normal 
Rats 
We next assessed whether repeated quetiapine administration differentially affected dopamine 
neuron activity in normal and CMS-exposed rats. As with acute administration of quetiapine, we 
observed a significant interaction between CMS exposure and repeated treatment with quetiapine 
(F(1,42)=5.2, p=0.028; Figure 12, Table 5). However, in contrast to the effects of acute treatment, 
repeated quetiapine treatment did not alter dopamine neuron population activity at these doses 
(CON-VEH-Repeated 0.99 ± 0.06 CPT, n=10; CON-QTP-Repeated 0.92 ± 0.10 CPT, n=13; 
t42=0.53, p=0.84; Table 5A, Figure 12). Similarly, no effect was observed in average dopamine 
firing rate (CON-VEH-Repeated 2.9 ± 0.21 Hz, n=78; CON-QTP-Repeated 3.4 ± 0.21 Hz, n=92; 
2-way ANOVA p>0.05 for main effects of drug or interaction; Figure 12B-D, Table 5). While a 
main effect of repeated quetiapine on proportion of burst activity was observed across all groups 
(F(1,301)=5.4; p=0.020), a post-hoc test within normal rats did not reveal a significant effect (CON-
VEH-Repeated 31.6 ± 2.9 %SIB, n=78; CON-QTP-Repeated 23.8 ± 2.6 %SIB, n=92; t(301)=2.0; 
p=0.084; Figure 12E-G, Table 5).  
 
 
 
 
  
65 
 
 
Figure 12. Impact of Repeated Quetiapine Administration in Normal and Chronically Stressed Rats 
Repeated administration of quetiapine for 21+ days reversed the CMS-induced decrease in dopamine population 
activity without affecting this measure in controls. A) Dopamine population activity was significantly increased in 
CMS-exposed rats following repeated quetiapine treatment, but was unchanged in control rats treated repeatedly with 
quetiapine. B-D) Average dopamine neuron firing rate was unchanged by chronic stress or quetiapine. E-G) Despite 
a significant main effect of Drug in 2-way ANOVA, post-hoc testing did not reveal significant changes in proportion 
of burst activity in either control or CMS rats treated repeatedly with quetiapine as compared to their respective control 
group treated repeatedly with vehicle. 
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Table 5. Summary of Dopamine Neuron Data for Repeated Quetiapine 
 
 
 
 
 
 
 
 
 
 
 
aMain effects among all groups;  
bSidak’s post-hoc test for drug effect (within same stress category); 
cSidak’s post-hoc test for stress effect (within same drug group); 
dMain effect not significant, post-hoc test not performed 
 CON-VEH-Chronic CON-QTP-Chronic CMS-VEH-Chronic CMS-QTP-Chronic 
Cells Per Track 0.99  0.060 0.92  0.10 0.58  0.070 0.93  0.11 
2-Way Interaction F(1,42) = 5.2 ; p = 0.028a - - - 
Drug Effect F(1,42) = 2.3; p = 0.13a t(42) = 0.53; p = 0.84b - t(42) = 2.7; p = 0.021b 
Stress Effect F(1,42) = 4.5; p = 0.040a - t(42) = 2.9; p = 0.011c t(42) = 0.11; p = 0.99c 
     
Firing Rate (Hz) 2.9  0.21 3.4  0.21 3.4  0.34 3.2  0.21 
2-Way Interaction F(1,42) = 1.5 ; p = 0.21a - - - 
Drug Effect F(1,42) = 0.22; p = 0.64a -d - -d 
Stress Effect F(1,42) = 0.23; p = 0.63a - -d -d 
     
Bursting (%SIB) 31.6  2.9 23.8  2.6 28.9  4.2 22.8  2.4 
2-Way Interaction F(1,301) = 0.077 ; p = 0.78a - - - 
Drug Effect F(1,301) = 5.4; p = 0.020a t(301) = 2.0; p=0.084b - t(301) = 1.3; p = 0.33b 
Stress Effect F(1,301) = 0.36; p = 0.55a - -d -d 
     
Group N  (Rats) N= 10 rats, 78 cells N = 13 rats, 92 cells N = 10 rats, 44 cells N = 10 rats, 91 cells 
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Rats exposed to CMS that received 21+ days of vehicle injections showed reduced 
dopamine neuron population activity compared to control rats treated repeatedly with vehicle 
(CON-VEH-Repeated 0.99 ± 0.06 CPT, n=10; CMS-VEH-Repeated 0.58 ± 0.07 CPT, n=10; 
t42=2.9, p=0.011; Figure 12A, Table 5). Consistent with the acutely-treated vehicle groups, CMS-
exposed rats repeatedly treated with vehicle were similar to control rats repeatedly treated with 
vehicle in average dopamine neuron firing rate (CON-VEH-Repeated 2.9 ± 0.21 Hz, n=78; CMS-
VEH-Repeated 3.4 ± 0.34 Hz, n=44; 2-way ANOVA p>0.05 for main effects of stress or 
interaction; Figure 12B-D, Table 5) and proportion of burst activity (CON-VEH-Repeated 31.6 ± 
2.9 %SIB, n=78; CMS-VEH-Repeated 28.9 ± 4.2 %SIB, n=44; 2-way ANOVA p>0.05 for main 
effects of stress or interaction; Figure 12E-G, Table 5).   
In rats exposed to CMS, repeated treatment with quetiapine increased dopamine population 
activity compared to CMS-exposed rats that received repeated treatment with vehicle (CMS-VEH-
Repeated 0.58 ± 0.07 CPT, n=10; CMS-QTP-Repeated 0.93 ± 0.11 CPT, n=13; t42=2.7, p=0.021; 
Figure 12A, Table 5).  This increase reversed the CMS-induced attenuation of dopamine neuron 
population activity to levels identical to that of control rats. Compared to rats treated repeatedly 
with vehicle, the rats that received repeated treatment with quetiapine did not show significantly 
altered average dopamine neuron firing rate (CMS-VEH-Repeated 3.4 ± 0.34 Hz, n=44; CMS-
QTP-Repeated 3.2 ± 0.21 Hz, n=91; 2-way ANOVA p>0.05 for main effects of drug or interaction; 
Figure 12B-D, Table 5) or proportion of burst activity (CMS-VEH-Repeated 28.9 ± 4.2 %SIB, 
n=44; CMS-QTP-Repeated 22.8 ± 2.4 %SIB, n=91; t301=1.3, p=0.33; Figure 12E-G, Table 5), 
despite a significant main effect of drug treatment across all groups for bursting (F(1,301)=5.4; 
p=0.020).  
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3.3.3 Experiment 3: Repeated Quetiapine Does Not Induce Depolarization Block in 
Normal Rats 
Repeated administration of antipsychotic drugs, including high doses of second generation agents 
such as quetiapine, have been shown to induce depolarization block following >21 of 
administration to normal rats. However, the induction of depolarization block following lower 
doses of quetiapine such as 10 mg/kg as used at present has not been examined. Thus, for a portion 
of the normal rats that received repeated treatment with quetiapine in Experiment 2, we tested for 
the presence of depolarization block at the conclusion of the dopamine neuron recording. 
Following an initial recording of dopamine neurons from 6-9 tracks within the A10 region, a 
presynaptic dose of apomorphine (40-80 g/kg) was administered via the lateral tail vein (infusion 
verified by a decrease in firing rate of a single recorded dopamine neuron), and an additional 6-9 
tracks of dopamine neuron recording was performed, allowing for pre- and post-apomorphine 
assessments of dopamine neuron population activity within the same animal. We observed no 
change in dopamine neuron population activity following apomorphine administration (Pre-APO 
0.75 ± 0.11 CPT; Post-APO 0.79 ± 0.14 CPT; paired t3=1, p=0.39; Figure 14), suggesting that 
depolarization block did not occur following repeated administration of 10mg/kg quetiapine.  
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Figure 13. Depolarization Block Does Not Occur with Repeated Antidepressant Doses of Quetiapine 
VTA dopamine neuron population activity was unchanged in rats sampled both pre- and post-apomorphine 
administration, suggesting no depolarization block was evident in control rats treated with quetiapine for 21+ days.  
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3.4 DISCUSSION 
In this study, we found divergent effects of acute and repeated administration of quetiapine 
in normal and CMS-exposed rats.  While acute quetiapine increased dopamine population activity 
in normal rats, it had no effect on CMS-exposed rats. Conversely, quetiapine administered 
repeatedly was uniquely capable of restoring normal levels of dopamine neuron population activity 
in CMS-exposed rats, but had no persisting effects on population activity in normal rats. 
Furthermore, we show that the normalization of dopamine neuron population activity in normal 
rats administered quetiapine for 21 days is unlikely to be due to the induction of depolarization 
block in VTA dopamine neurons.  
Prior studies have administered quetiapine to CMS-exposed rats and observed behavioral 
effects consistent with an antidepressant action (Orsetti et al., 2007). However, as far as we are 
aware, this is the first study to examine the electrophysiological impact of quetiapine on the 
dopamine system in rats exposed to an animal model of depression.  Our results suggest that 
quetiapine has significantly different effects on the dopamine system in CMS-exposed rats as 
compared to its effects in normal rats. These data add to existing literature on the dopamine system 
impact of acute and repeated quetiapine treatment in normal rats. These studies found that acute 
administration of quetiapine at doses of 10 mg/kg or greater will induce acute increases in 
population activity of the A10 (i.e., VTA) but not A9 (i.e., substantia nigra) dopamine neurons 
(Goldstein et al., 1993). Moreover, the impact of repeated administration of quetiapine was 
examined at increasing dosages, and found to induce depolarization inactivation only when 
administered at doses of 40 mg/kg or greater (Skarsfeldt, 1995). This higher dose is more in line 
with the doses used clinically in the treatment of psychosis or acute mania (i.e., 600-800mg), 
whereas the dose used in the treatment of depression (i.e., 300mg) is more in line with the 10 
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mg/kg dose used in the present study, as measured by D2 receptor occupancy (Kapur, VanderSpek, 
Brownlee, & Nobrega, 2003).  
The mechanism of the increase in dopamine population activity with acute or repeated 
treatment with quetiapine, like other D2RA’s, is thought to be primarily due to heightened 
presynaptic drive via feedback loops originating in the limbic striatum, as lesions of these feedback 
pathways block the antipsychotic drug-induced increase in population activity (Bunney & Grace, 
1978). Similarly, the mechanism for the induction of depolarization block is thought to be a 
markedly enhanced overdrive of this pathway, resulting in elevation of the resting membrane 
potential of dopamine neuron cell bodies to levels that do not allow for the propagation of electrical 
impulses due to persistently inactivated voltage-gated sodium channels (Grace et al., 1997). Thus, 
one plausible therapeutic mechanism for quetiapine and other D2RA medications that function as 
antidepressants is that at the low doses used, they are utilizing these same feedback pathways to 
stimulate dopamine neuron activity, but not overdriving neurons to the point of depolarization 
block. Moreover, because many of these neurons are starting in a pathologically hyperpolarized 
state (reflecting the lower number that are spontaneously active), the effect of persistent afferent 
stimulation would be expected to ultimately lead to normalized levels of dopamine neuron 
population activity. We propose that the low level of D2 blockade without inducing depolarization 
block occurring with low doses of quetiapine is compensated homeostatically by increased D2 
receptor number, increased dopamine synthesis, and increased release. As a result, the 
normalization of dopamine neuron population activity produces a greater restoration of  phasic 
dopamine system responsivity to afferent drive (Grace, 2016) compared to the low tonic level of 
receptor blockade. 
 
72 
The principle brain region believed to impact VTA dopamine population activity is the 
ventral pallidum (VP), as pre-infusion of the GABA-A receptor antagonist into the VP blocks the 
increase in dopamine population activity observed following acute administration of sertindole or 
haloperidol (Valenti & Grace, 2010). Thus, D2RAs are hypothesized to enhance accumbal 
inhibitory drive of the VP, releasing dopamine neurons from VP inhibition and subsequently 
increasing the number that are spontaneously active. We have shown previously that the VP is also 
a critical node in the pathway driving the CMS-induced hypodopaminergic state (Chang & Grace, 
2014). Therefore, these collective data lead to the intriguing possibility that convergent and 
counteracting effects on the VP is the mechanism of action of these D2RA medications’ 
antidepressant effects, with CMS increasing and quetiapine decreasing VP inhibitory tone over 
VTA dopamine neurons.  
The approach of using subsets of D2RA medications for an antidepressant effect is a 
promising therapeutic mechanism. The present study focused only on quetiapine rather than other 
D2RAs such as haloperidol or clozapine because quetiapine has been shown to possess 
antidepressant effects clinically (Komossa, Depping, Gaudchau, Kissling, & Leucht, 2010). Like 
other second-generation atypical antipsychotic drugs, quetiapine induces changes in activity 
relatively selectively at VTA (i.e. A10) dopamine neurons, whereas first generation antipsychotics 
such as haloperidol act on both the nigrostriatal (i.e., A9) and mesolimbic A10 dopamine neurons 
(Chiodo & Bunney, 1983; Goldstein et al., 1993), which is the likely reason for the greater 
preponderance of motoric side effects of the first generation antipsychotics. Moreover, the binding 
profile of quetiapine is much different than other D2RA antipsychotic drugs, even within the 
second generation (atypical) class (Lako, van den Heuvel, Knegtering, Bruggeman, & Taxis, 
2013). Thus, quetiapine demonstrates a unique receptor occupancy curve wherein it binds 
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fleetingly with high potency and rapid dissociation, rather than a prolonged occupancy seen with 
other compounds (Kapur, Zipursky, Jones, Shammi, et al., 2000). It is possible that these additional 
collective qualities may account for the unique ability of quetiapine to act as an antidepressant 
medication while haloperidol and other more traditional antipsychotic drugs are not effective as 
antidepressants.  
In conclusion, the present data support unique and divergent effects of acute and repeated 
administration of the D2RA quetiapine in normal and chronically stress-exposed rodents. These 
data offer compelling evidence for further investigating the dopaminergic component of the 
therapeutic mechanism of select D2RA medications, and highlight the importance of conducting 
these studies using an animal model of depression in addition to normal rats.  
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4.0  GENERAL DISCUSSION 
4.1 SUMMARY OF FINDINGS 
In the first portion of this dissertation, we evaluated the dopamine regulating roles of two brain 
regions with significant clinical evidence for involvement in MDD. We found these two regions 
have distinctly different effects on subpopulations of dopamine neurons. Next we expanded on 
these observations from normal rats to investigate whether either region drives CMS-induced 
decreases in dopamine population activity.  We observed that inactivation of the ILPFC but not 
LHb reversed CMS-induced deficits in dopamine population activity, suggesting a greater role for 
the ILPFC relative to the LHb in CMS-induced dopamine system deficits. Finally, we examined 
the effects of acute and repeated treatment with quetiapine in rats exposed to CMS. We found that 
repeated but not acute treatment restored normal dopamine neuron population activity in CMS-
exposed rats. We now discuss the implications of these findings for the circuitry of MDD and its 
treatment. 
4.2 CIRCUITRY IMPACTING DOPAMINE IN MDD 
4.2.1 ILPFC/BA25 
The ILPFC has received considerable attention recently as an important node in depressive 
features and antidepressant-related effects in rodent studies. The unique ability of the ILPFC to 
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restore dopamine activity after CMS in this work helps clarify a number of recent studies. Ferenczi 
et al. (2015) examined the impact of ILPFC activation on dopamine-related behavioral measures 
of reward sensitivity relevant to depression, as well as the ability of ILPFC activation to modulate 
dopaminergic drive on downstream targets as assessed via opto-fMRI in one of the first 
applications of the approach. They found that induction of moderate but sustained elevation of 
ILPFC activity using a step-function opsin induced behavioral deficits in sucrose preference, social 
interaction, and real-time conditioned place preference for optically driven dopamine stimulation, 
suggesting that ILPFC activation dampened the typical dopaminergic response associated with 
these activities. This interpretation was further supported by opto-fMRI data suggesting a 
diminished post-synaptic induction of activity in the striatum. Finally, local field potentials 
recorded in the ILPFC and striatum showed an increase in gamma band coherence between these 
regions during ILPFC activation, suggestive of enhanced functional connectivity.  Thus, these data 
support a functional significance for our observed decrease in dopamine population activity 
following ILPFC activation at both the behavioral and systems levels.  
It is also interesting to compare the results from our studies to recent papers investigating 
antidepressant mechanisms of ILPFC DBS or ketamine microinfusion. Hamani et al (2010) 
showed that deep brain stimulation but not inactivation of the entire mPFC was able to reverse 
CMS induced behaviors (Hamani et al., 2010). However, we have previously shown that 
inactivation of the two regions comprising the mPFC - i.e. the ILPFC and the prelimbic prefrontal 
cortex (PLPFC) - has opposite effects on the dopamine system, with ILPFC inhibition increasing 
and PLPFC inhibition decreasing VTA dopamine neuron population activity (Patton et al., 2013).  
Thus that group’s concurrent inactivation of the PLPFC likely canceled out any antidepressant 
effect of ILPFC inactivation. More recently, Fuchikami et al (2015) showed that microinfusion of 
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ketamine into the ILPFC induced antidepressant effects comparable to systemic administration, 
and that 1-hour of high frequency ILPFC stimulation using optogenetics also mimicked the 
antidepressant effect of ketamine examined multiple days later. However, the stimulation protocol 
used in this study aimed to recreate ketamine’s effect on plasticity within ILPFC microcircuitry 
(Fuchikami et al., 2015), rather than simple activation of the region as was performed by Ferenczi 
et al (2015) and is more reflective of the NMDA microinfusion used in the present work. Thus it 
is not surprising that they observed an anti-depressive effect with their ILPFC stimulation protocol. 
Finally, that study is further complicated by the recent discovery that the antidepressant effect of 
ketamine is not due to its NMDA antagonism properties per se, but rather the effects of a metabolite 
(Zanos et al., 2016). 
4.2.2 LHb 
Although the LHb has been an intense focus of investigation, the present study is the first 
to systematically evaluate the changes in firing properties of the overall population of VTA 
dopamine neurons that occur with persistently elevated LHb activation over a period of 1-3 hours. 
In contrast, prior studies examining the ability of the LHb to inhibit dopamine neurons have 
focused on reductions in firing rate with LHb stimulation.    The most likely mechanism for this 
inhibition would be the LHb activating the RMTg, leading to enhanced efferent inhibitory drive 
over VTA dopamine neurons. Based on our observed data, we propose this effect would be 
strongest when directed at dopamine neurons located in lateral VTA.  
Based largely on data collected in non-human primates, a role has been proposed for the 
LHb for inhibiting dopamine neurons in response to a negative reward prediction error, i.e. to 
signal disappointment when an expected reward was not delivered. Thus, considering that the 
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behavioral roles of the LHb that have been proposed emphasize phasic responses to inhibit 
dopamine neurons acutely in response to individual stimuli, rather than for creating a set point at 
steady-state, one might think it seems counterintuitive that LHb activation induced a reduction in 
the number of dopamine neurons firing but did not reduce their firing rate or amount of bursting. 
In contrast, a slight increase in firing rate in medial dopamine neurons was observed.  
In order to reconcile these findings, one must consider the nature of the circuit interrogation 
performed in the current experiments. In this study, we chose to use NMDA to create a more 
persistent increase in LHb activity, rather than phasic increases in activity as have been performed 
previously using optogenetics or electrical stimulation. A manipulation such as we performed 
would therefore be expected to provide a better estimation of the persisting effect of LHb activity 
as would be expected to occur if this region were persistently overactive, as has been hypothesized 
to be the case in MDD. Thus, the findings from this experiment suggest that the LHb, when 
tonically activated at higher levels, regulates tonic drive of dopamine neurons located only in 
lateral VTA. As discussed earlier, these neurons have a greater extent of projections to associative 
striatum and involvement in cognitive tasks, whereas the more medially located dopamine neurons 
project more heavily to ventral striatum and are more likely to invigorate motivational states. Thus, 
the present findings suggest pathological activation of the LHb would be more likely to result in 
diminished cognitive reserve than motivational drive, per se. Furthermore, the lack of overlap of 
the neurons inhibited by LHb activation and those inhibited by CMS suggest the LHb would not 
be involved in mediating chronic stress-induced dopamine system hypofunction. This hypothesis 
was supported by our data demonstrating that LHb inactivation did not restore dopamine neuron 
population activity to normal levels in rats exposed to CMS. 
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Importantly, our results do not rule out a role for the LHb in all aspects of depression. 
Rather, we have shown that the LHb is not involved in lowering the gain of the dopamine system 
in response to chronic stress. This actually makes sense given that most literature ties the LHb to 
decision making and other cognitive functions, and not modulating motivational drive. Finally, 
there is still potential for the LHb to be involved in the pathophysiology of depression in other 
ways such as mediating dysfunction in the serotonin system via its influence over the dorsal raphe.   
4.2.3 ILPFC-LHb Interactions 
Given the existence of a projection from the ILPFC to the LHb that drives FST immobility 
(Warden et al., 2012), an intriguing consideration could be that this projection has some role in 
driving dopamine neuron inhibition. However, our present data would argue against this notion on 
two grounds. First, if the ILPFC to LHb projection were driving a decrease in dopamine population 
activity, one would expect to see overlap in the location of the dopamine neurons inhibited when 
either the ILPFC or LHb were activated in normal rats. However, in the present data, ILPFC 
activation inhibited dopamine neuron population activity in medial VTA and increased bursting in 
lateral VTA, whereas LHb activation inhibited dopamine neuron population activity exclusively 
in lateral VTA and slightly increased the firing rate of dopamine neurons in medial VTA. Thus 
there were no common effects on VTA dopamine neurons with activation of these two structures 
to suggest a shared projection pathway. Second, if the ILPFC to LHb projection were driving the 
observed decrease in dopamine neuron population activity in CMS-exposed rats, one would expect 
to see restoration of normal dopamine neuron population activity by interrupting this circuit with 
inactivation of either the LHb or ILPFC. However, we found that in rats exposed to CMS, 
inactivation of only the ILPFC restored dopamine neuron population activity to normal levels, 
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whereas LHb inactivation had no effect. Thus, while the ILPFC to LHb projection may possess 
the ability to drive depressive-related behaviors, the present results do not support a role for this 
circuit in altering dopamine neuron firing properties.  
4.2.4 Integration of Circuitry Regulating Dopamine in CMS 
Our data on the effects of inactivating the ILPFC or LHb in rats exposed to CMS adds to a growing 
body of literature on the circuitry regulating dopamine population activity and potential points of 
pathology in disease states that alter dopamine system function (Grace, 2016).  
Specifically, the finding that ILPFC inactivation in CMS-exposed rats restores dopamine 
population activity by potentially increasing the activation of dopamine neurons across the extent 
of the VTA is particularly intriguing. It has been demonstrated in experiments with normal rats 
that inactivation of the ILPFC drives an increase in the number of spontaneously active dopamine 
neurons via a circuit that traverses the thalamic nucleus reunions en route to the vSub of the 
hippocampus (Zimmerman & Grace, 2016). Given that the vSub has the ability to drive increases 
in dopamine population activity across the medial/lateral extent of the VTA (Valenti et al., 2012), 
the present data argue for a role of the vSub in restoring normal levels of dopamine population 
activity after CMS via ILPFC inactivation.  
In other neuropsychiatric disorders, it has become apparent that most treatments do not 
reverse the site of primary pathology, but rather induce offsetting synaptic plasticity (Bowers & 
Ressler, 2015). Thus, treatments that reduce BA25 activity may result in a resolution of depressive 
symptoms, however, the underlying susceptibility of that individual to develop depression still 
remains (Holtzheimer & Mayberg, 2011b). This would be expected to contribute to the high rate 
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of recurrence of depression in patients who previously underwent successful treatment, 
particularly when they are not maintained on treatment following the resolution of symptoms.   
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Figure 14. Summary of Circuitry Involved in CMS 
In the normal state, afferent regions are functioning at baseline levels, resulting in normal levels of VTA dopamine neuron population 
activity. When activated, the ILPFC preferentially inhibits dopamine neurons located in medial VTA, whereas the LHb preferentially inhibits 
dopamine neurons located in lateral VTA. Chronic stress leads to overdrive of the ILPFC, which via the BLA and VP, reduces dopamine 
population activity in medial VTA. The functional implication of the transition of these dopamine neurons into a silent inactive state is 
decreased availability to fire when presented with reward-related stimuli. This is proposed to correlate with the blunted response to rewarding 
stimuli reported by patients with depression. ILPFC inactivation after CMS halts this pathology as well as activates the countervailing 
vSub/NAc pathway to restore normal VTA activity. 
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4.3 QUETIAPINE CIRCUIT EFFECTS IN MDD 
4.3.1 Insights from Mechanisms in Schizophrenia 
The antidepressant effect of quetiapine was discovered incidentally in studies of its use for patients 
with schizophrenia. While the dopamine system pathology in schizophrenia and MDD are most 
likely different, if not opposite, we can still gain insight into the mechanism of quetiapine’s 
antidepressant effect by examining its impact on dopamine regulating circuitry in the context of 
schizophrenia.  
4.3.1.1 Time Course 
In schizophrenia, there is increased dopamine system activity, which animal models 
suggest is driven by an increase in the number of dopamine neurons that are spontaneously active 
(Grace, 2015). One currently accepted conceptualization of how this manifests symptomatically 
as schizophrenia is that the excessive dopamine signaling results in the attribution of “aberrant 
salience” to environmental stimuli that otherwise should not be of significant interest to the subject, 
which is expected to result in positive symptoms such as paranoia (Kapur, 2003). D2RAs reduce 
dopamine transmission, with resulting decreases in positive symptoms (Kapur, Agid, Mizrahi, & 
Li, 2006). 
The mechanism of quetiapine’s antipsychotic effect is thought to be due to blockade of 
dopaminergic transmission in the striatum, which leads to enhanced feedback to further increase 
dopaminergic drive, and ultimately induces a state of depolarization block (Grace et al., 1997). 
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Clinically this effect is observed within hours to days (Kapur et al., 2005). This was perplexing, 
because when the D2RA induction of depolarization block is examined in normal rats, this 
phenomenon takes 21 days to develop (Bunney & Grace, 1978). The notion that the time course 
of D2RA effects may differ between normal subjects and those with schizophrenia emerged when 
the effects of D2RA medications were examined in a rodent model of schizophrenia that features 
a prominent hyperdopaminergic state. Using the MAM model, it was observed that D2RAs 
induced depolarization block in dopamine neurons after the first dose, whereas in normal rats, this 
process takes 21 days (Valenti, Cifelli, et al., 2011). Thus, because the set point of the dopamine 
system was already at an elevated state, it appears the system was more easily pushed into 
depolarization block. 
 
4.3.1.2 D2R Occupancy 
One of the most interesting features of quetiapine as compared to other medications in the D2RA 
class is the time course of its binding to the dopamine D2R. Thus, for most D2RA APDs, binding 
is initiated and persists at a relatively stable level, with gradual drop off as the drug is metabolized 
(Ginovart & Kapur, 2012). Conversely, quetiapine binds to the D2R at a high level of occupancy 
within the first 4 hours, and then its occupancy rapidly decreases (Kapur, Zipursky, Jones, 
Shammi, et al., 2000). These data were intriguing, because it was thought that in order for a D2RA 
to have an APD effect, it needed to have a persistent D2R occupancy above 65% (Kapur, Zipursky, 
Jones, Remington, & Houle, 2000). However, quetiapine appeared to only maintain occupancy 
above 60% for a very short period of time. This observation led to the proposal that persistently 
high levels of D2R occupancy were not required for antipsychotic effects to be maintained over 
time (Remington & Kapur, 2010). Instead, it seems that induction of therapeutic depolarization 
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block of dopamine neurons can be achieved reliably with only brief but repeated exposure to high 
levels of D2R occupancy (Tauscher-Wisniewski et al., 2002).  
4.3.2 Synthesis of Potential Antidepressant Mechanism 
As summarized above, most of our understanding of the pharmacological properties of quetiapine 
were revealed from studies of the mechanisms of its antipsychotic effect, and these efforts yielded 
a number of observations that should prove useful in discerning its antidepressant effect.  
4.3.2.1 Impact of State of Dopamine System 
As discussed previously, the baseline state of the dopamine system at time of D2RA administration 
has a profound impact on the subsequent effect on dopamine neuron population activity. While in 
schizophrenia, the dopamine system is hyperactive, in MDD, the dopamine system is hypoactive. 
Our lab’s results from converging lines of research across different stress-induced animal models 
of MDD suggests that this dopamine system hypoactivity is observed clinically because fewer 
dopamine neurons are spontaneously active in patients with MDD, resulting in lower levels of 
tonic activation of the dopamine system as well as reduced capacity for phasic response, given that 
only spontaneously active dopamine neurons are capable of burst firing to salient stimuli. 
 In the present experiments, we observed that quetiapine administered at antidepressant 
doses (10 mg/kg) to CMS-exposed rats had no acute effect on the number of spontaneously active 
dopamine neurons, but restored a normal number of spontaneously active dopamine neurons with 
repeated administration for 21+ days. These data suggest that in a hypodopaminergic state, the 
time course for dopamine system recovery with D2RA treatment is longer than in a 
hyperdopaminergic state, where effects are observed immediately.  
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It is tempting to speculate that perhaps the substantially lower dose of quetiapine when 
used for antidepressant treatment may be to blame for the lack of an acute effect. However, the 
collective data from a multitude of clinical trials would argue against this. Thus, in the patients 
studied in the pivotal placebo-controlled randomized clinical trials, doses of 150 mg/day were most 
effective when quetiapine was used as monotherapy, and doses of 300 mg/day were most effective 
when quetiapine was used as augmentation to existing SSRI or SNRI therapy. These doses are far 
lower than those used for quetiapine in the treatment of schizophrenia (i.e. >800 mg/day), and 
increasing doses resulted in no additional antidepressant effect. Thus, it would appear that the lack 
of an acute increase in dopamine population activity in CMS-exposed rats is more likely due to a 
greater time requirement for duration of treatment, rather than an increased dose requirement per 
se. This notion is also supported by the clinical trials, where antidepressant effects were observed 
over 1-6 weeks, with very few patients reporting acute improvements in mood. The reason for this 
longer time course remains unclear, but may have to do with time requirements for plasticity to 
occur in striatal feedback circuitry, discussed in greater detail below. 
The reason for the difference in dose requirements in the clinical trials when quetiapine 
was used as augmentation vs. monotherapy remain unclear. One possibility could be that there is 
greater degree of dopamine system pathology in the patients who failed initial SSRI/SNRI therapy 
and thus qualified for a trial of quetiapine augmentation, and this was better addressed by a higher 
dose of quetiapine. Another possibility could be that concurrent treatment with other 
antidepressant medications interfered with quetiapine’s effect on a pharmacological basis, as 
increased synaptic levels of serotonin due to SSRI therapy could potentiate inhibitory effects of 
serotonin on dopamine release, thus necessitating a larger quetiapine dose to overcome this added 
dopamine-reducing effect. 
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4.3.2.2 Common Circuitry of Dopamine Regulation 
All D2RAs induce increases in dopamine population activity via induction of greater NAc 
inhibitory tone over the VP and subsequent disinhibition of VTA dopamine neurons, which 
appears to result from striatal post-synaptic D2R blockade. We have shown that in rats exposed to 
CMS, there is increased VP inhibition of VTA dopamine neurons, which is the reason that fewer 
are spontaneously active (Chang & Grace, 2014). These effects occurring concurrently raise the 
potential for an intriguing interaction between these two opposing influences over VP activity, 
wherein CMS drives and quetiapine inhibits VP activity. Such an effect would explain why 
quetiapine worked to increase dopamine population activity in CMS-exposed rats, i.e. that it 
resulted in strengthening of opposing synaptic plasticity of NAc afferents onto the VP, thus 
restoring normal levels of VP inhibitory tone onto the VTA. Furthermore, this hypothesis is 
supported by both clinical and pre-clinical data supporting the effectiveness of quetiapine in 
presently depressed/CMS-exposed subjects, as well as in maintenance therapy of patients who 
remitted from depression or rats treated at the onset of exposure to CMS (Orsetti et al., 2007). 
Thus, it would appear that quetiapine has the ability both to counteract existing pathologically 
increased VP activity, as well as prevent its onset in individuals susceptible to its development. 
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4.4 FUTURE DIRECTIONS 
4.4.1 Circuit Explorations 
A major point that has emerged from our lab’s inquiry into the circuitry driving downregulation 
of the dopamine system in depression is how specifically information flows through the different 
nodes that we have identified. Thus, while the impact of ILPFC activation has been shown to 
depend on intact glutamatergic afferents to the BLA, and the effect of BLA activation depends on 
glutamatergic afferents to the BLA, it remains possible that other intermediary regions could also 
be involved. In one study, the projection from ILFPC to amygdala was shown to reduce anxiety, 
but overlap between specific amygdala subregions our group has examined and those studied in 
that paper remain unclear (Adhikari et al., 2015). This is important, as different circuits through a 
given region often have been shown to have distinct or opposite effects (Stuber et al., 2011).  
 
4.4.2 Pharmacology Explorations 
While the present study offers some insight into the potential mechanism of quetiapine’s 
antidepressant effect, many questions still remain. Among the most critical is a determination of 
what specific pharmacological properties of quetiapine drive its uniquely potent antidepressant 
effect among the D2RA medications. 
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4.5 FINAL REMARKS 
In this dissertation research we performed an in-depth examination of the impact of clinically 
relevant circuits modulating dopamine function and their relation to the CMS rodent model of 
depression. We also assessed the effects of novel D2RA treatment approaches for MDD and 
possible mechanisms of their effect in the CMS model.  Together, these data offer insights into 
stress-induced dopamine system deficits in the context of MDD. Future efforts will continue to 
leverage these pathways to explore mechanisms of dopaminergic changes in MDD and guide 
efforts towards their remediation.  
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